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ABSTRACT 
 
Arenaviruses merit significant attention both as powerful models to study viral pathogenesis and as 
important human pathogens. Lymphocytic choriomeningitis virus (LCMV) infection of its natural host, 
the mouse, represents a powerful experimental system that provided novel concepts in immunology 
and virology that have been extended to other viruses, bacteria, and parasites. With over 200, 000 
infections per year and several thousand deaths, Lassa virus (LFV) is by far the most important among 
the human pathogenic arenaviruses and represents a severe threat for human health. There are no 
licensed arenavirus vaccines and the current therapies are not optimal. Therefore, it is important to 
develop better antiviral drugs to combat the threats of arenavirus infections. 
A fundamental reason for the high mortality of infections with human pathogenic arenaviruses is a 
failure of the host’s immune system to control viral replication, leading to an unchecked viremia 
associated with hemorrhagic disease. Since rapid dissemination of the virus critically depends on 
attachment and entry into host cells, drugs targeting these steps will give the host’s immune system a 
wider window of opportunity for the generation of an efficient anti-viral immune response. The goal of 
my research was therefore the development of novel anti-viral drugs that are able to block these initial 
steps of infection. In a first approach to identify such “gatekeeper” drugs I performed high-throughput 
small molecule screening using combinatorial chemical libraries, which represent a powerful 
technology for discovery of specific inhibitors of receptor-ligand interactions. In a collaborative effort 
with the laboratory of Dr. Dale Boger (Department of Chemistry, Scripps) I used a high-throughput 
screening assay for inhibitors of LFV infection using retroviral pseudotypes containing LFVGP in their 
envelope and a luciferase reporter gene. My screening identified several small molecule compounds 
that show specific blocking of LFV infection in several human and primate cell types with IC50 values 
in the range of 1-10 µM. Some of the candidates were also active against retroviral pseudotypes the 
South American hemorrhagic fever viruses Junin, Machupo, and Guanarito.  
In a second approach, I evaluated the activity of anionic polymers like heparin, dextrane sulfate, and 
fucoidan, previously shown to have anti-viral effects, against human pathogenic arenaviruses. In 
contrast to published data, I found no significant activity of heparin and heparan sulfate against 
arenavirus infection and could demonstrate that heparan sulfate and other glycosaminoglycans are 
generally not involved in arenavirus infection. Dextrane sulfate and fucoidan indeed showed some 
anti-viral activity, however, they were far less efficient than claimed by other researchers. This 
motivated me to start to evaluate novel polymer drugs for activity against arenaviruses.  
 ix
Introduction 
A. INTRODUCTION 
 
Viral infectious diseases have threatened humankind throughout our existence. Although advances in 
medical science have changed the demographics of mortality with an increase in life expectancy to 
more than seventy-five years in the developed world, viral infections are still rampant in 
underdeveloped countries with life expectancies of less than 40 years in the poorest nations. Beyond 
contributing to mortality, viral infections also leave affected individuals often physically and mentally 
disabled, exacerbating human suffering and the socio-economic impact caused by these diseases.  
 
A.1 Arenaviruses 
 
A.1.1 Classification of arenaviruses 
 
Two major groups of arenaviruses are currently recognized: the Old World arenaviruses with 
lymphocytic choriomeningitis virus (LCMV) and Lassa fever virus (LFV) as representatives and the 
larger group of the New World arenaviruses, which are divided into three major Clades, A, B, and C 
(Buchmeier et al., 2001).  LCMV infection of its natural host, the mouse, represents a powerful 
experimental system that provided novel concepts in immunology and virology that have been 
extended to other viruses, bacteria, and parasites (Buchmeier et al., 2001; Oldstone, 2002). LCMV is 
also a prevalent human pathogen and congenital infections of the central nervous system by LCMV are 
considered an important problem in human pediatric medicine. 
Arenaviruses are also the causative agents of several severe hemorrhagic fevers (HF) with high 
mortality in humans (Buchmeier et al., 2001; Geisbert and Jahrling, 2004). Lassa fever is the second 
most important human viral HF after Dengue and affects an estimated 180 million individuals living in 
its endemic regions in Western Africa. With over 200, 000 infections per year and several thousand 
deaths, LFV represents a severe threat for human health and a major humanitarian problem 
(McCormick and Fisher-Hoch, 2002). There is currently neither an efficient cure nor an efficacious 
vaccine for this disease and survivors are often left with substantial neurological impairment. Among 
the New World arenaviruses, Junin virus causes Argentine HF, and is a serious public health problem 
in Argentina. Machupo virus causes Bolivian HF, and Guanarito and Sabia virus have emerged as 
etiological agents of severe HF in Venezuela and Brazil, respectively. Infections with these 
arenaviruses in humans result in high mortality of 15 to 30%. Apart from the severe humanitarian 
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burden caused in endemic regions, air travel regularly imports arenavirus HF cases into metropolitan 
areas around the globe, placing local populations at risk. 
 
 
Figure A1: phylogenetic tree of arenaviruses. Left: electron microscopic image of a typical arenavirus particle 
and a list of the human pathogenic arenaviruses. Right: Phylogenetic tree of the arenavirus family, displaying 
the major subgroups and Clades.   
 
A.1.2 Structure, genome and proteins of arenaviruses 
 
Arenaviruses are enveloped viruses with a bisegmented negative single-stranded RNA genome and a 
life cycle restricted to the cell cytoplasm. Virions are pleomorphic but typically spherical with an 
average diameter of 90 to 110 nm, and are covered with surface glycoprotein spikes. Virions enclose 
the genomic RNAs as helical ribonucleoprotein structures in circular configurations. Virus particles 
have a “sandy” appearance from which the family name is derived. 
Each genomic RNA segment, L (ca 7.3 kb) and S (ca 3.5 kb), uses an ambisense coding strategy to 
direct the synthesis of two polypeptides in opposite orientation, separated by an intergenic region 
(IGR) with a predicted folding of a stable hairpin structure (Fig. A2). The S RNA encodes the viral 
glycoprotein precursor, GPC, (ca 75 kDa) and the nucleoprotein, NP, (ca 63 kDa), whereas the L RNA 
encodes the viral RNA dependent RNA polymerase (RdRp, or L polymerase) (ca 200 kDa), and a 
small RING finger protein Z (ca 11 kDa). The NP and L coding regions are transcribed into a genomic 
complementary mRNA, whereas the GPC and Z coding regions are not translated directly from 
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genomic RNA, but rather from genomic sense mRNAs that are transcribed using as templates the 
corresponding antigenome RNA species, which also function as replicative intermediates. The LCMV 
mRNAs have extra non-templated nucleotides (nt) and a cap structure at their 5’-ends, but the origin of 
both the cap and 5’-non-templated nt extensions remain to be determined. Transcription termination of 
subgenomic non-polyadenylated viral mRNAs has been mapped to multiple sites within the distal side 
of the IGR, suggesting that the IGR acts as a bona fide transcription termination for the virus 
polymerase. A widely accepted model for the control of Arenavirus RNA replication and gene 
transcription proposes that at early times of infection, low levels of NP prevents the virus polymerase 
to go across the IGR, and hence transcription is favored over replication. Increasing intracellular NP 
levels during the course of the infection would unfold secondary RNA structures within the IGR. This 
would attenuate structure dependent transcription termination at the IGR, thus promoting replication of 
genome and antigenome RNA species. 
 
Figure A2: Schematic of arenavirus particles and their genome organization. For details see text. (Image 
provided by Dr. Juan-Carlos de la Torre, Scripps Research Institute). 
 3
Introduction 
A.1.3 The GP of arenaviruses mediates host cell attachment and entry  
 
The arenavirus glycoprotein precursor GPC is coded in the S segment and synthesized as a single 
polypeptide chain. GPC is then post-translationally cleaved by the cellular protease SKI-1/S1P cellular 
protease to yield the two mature virion glycoproteins GP-1 (40-46 kDa) and GP-2 (35 kDa) (Lenz et 
al., 2001; Beyer et al., 2003; Kunz et al., 2003). GP-1 is located at the top of the spike, away from the 
membrane, and is held in place by ionic interactions with the N-terminus of the transmembrane GP-2, 
that forms the stalk of the spike (Fig. A3) GP-1 is the virion attachment protein that mediates virus 
interaction with host cell surface receptors. 
Upon receptor binding, arenavirus virions are internalized by uncoated vesicles and released into the 
cytoplasm by a pH-dependent membrane fusion step (Borrow et al., 1994). The pH-dependent fusion 
between viral and cell membranes in the acidic environment of the endosome is mediated by the GP2 
portions of arenavirus GPs.  
Based on their structure-function relationship, viral proteins mediation membrane fusion have been 
classified to belong to either class I or class II fusion proteins. The class I fusion proteins are translated 
at GP precursor proteins, which are proteolytically processed to give rise to metastable trimers 
consisting of GP1/GP2 heterodimers. Whereas the peripheral head subunit mediates receptor binding, 
the transmembrane subunit is responsible for membrane fusion itself. Destabilization sets off a series 
of conformational rearrangements within the transmembrane subunit leading to the formation of the 
post-fusion six-helix bundle conformation. This state is characterized by C-terminal α-helices packing 
into the hydrophobic grooves of a trimeric coiled-coil core, formed by N-terminal α-helices (Fig. A3). 
Thereby, the viral envelope and the target membrane are drawn together to give rise to the fusion pore. 
Cross-linking experiments carried out with purified LCMV indicated that the GP-1/GP-2 heterodimers 
would form tetramers, which were partly disulfide linked among their GP-1subunits (Burns and 
Buchmeier, 1991). However, more recent work clearly demonstrated the presence of two alpha-helices 
separated by a glycosylated peptide loop within the ectodomain of arenavirus GP2 forming a trimeric 
pre-fusion complex (Gallaher et al., 2001; Eschli et al., 2006) (as shown in Fig.A3). 
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Figure A3:  Proposed class I model of the arenavirus GP. (A) Arenavirus GP in its hypothetical pre-fusion 
state. GP-1 forms the globular head subunit, whereas GP-2 forms the membrane fusion-mediating subunit. GP-1 
is covered by a dense carbohydrate shield, with the exception of the receptor binding site, depicted in red. (B) 
GP spike in its hypothetical low-energy post-fusion state, after formation of the viral fusion pore. The membrane 
of the infected host cell is colored in yellow and the viral membrane in light gray. The GP-2 subunit is shown in 
its predicted six-helix bundle conformation; thus, the α-helix 2 packs in an anti-parallel fashion into the grooves 
of the N-terminal coiled-coil core. Taken from Eschli et al., (2006). 
 
A.1.4 Alpha-dystroglycan is the cellular receptor for arenaviruses  
 
The first cellular receptor for LFV, LCMV and Clade C New World arenaviruses is α-dystroglycan (α-
DG) (Cao et al., 1998; Spiropoulou et al., 2002), the extracellular part of dystroglycan (Fig. A4). DG 
was initially identified as the central component of the dystrophin-glycoprotein complex (DGC) in the 
membrane of skeletal muscle (Barresi and Campbell, 2006). In vertebrates, DG is encoded as a single 
protein, which is cleaved into α-DG, a peripheral protein, and β-DG, a membrane protein (Fig. A4A). 
DG is expressed in most developing and adult tissues and provides a molecular link between the 
extracellular matrix (ECM) and the actin-based cytoskeleton (Fig. A4B).  
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Figure A4: Schematic representation of DG (A) and a DG complex with the ECM protein laminin (B). 
(modified from Kevin Campbell, Howard Hughes Medical Institute, University of Iowa).  
 
A.2 Lassa fever represents a severe threat for human health and a major humanitarian problem 
 
Lassa fever is the second most important human viral HF after Dengue and affects an estimated 180 
million individuals living in its endemic regions in Western Africa. With over 200, 000 infections per 
year and several thousand deaths, LFV represents a severe threat for human health and a major 
humanitarian problem (McCormick and Fisher-Hoch, 2002; Geisbert and Jahrling, 2004). There is 
currently neither an efficient cure nor an efficacious vaccine for this disease and survivors are often left 
with substantial neurological impairment.  
LFV was first isolated in 1969 after a hospital outbreak in northern Nigeria and is classified within the 
Old World arenavirues. The natural reservoir of Lassa fever virus (LFV) is the rodent Mastomys 
natalensis and LF is endemic in Sierra Leone, Liberia, and Nigeria, where it represents a major cause 
of death. The fatality rate of LF in hospitalized patients is >15%, rising to more than 50% in some 
outbreaks. In recent years, air travel resulted in the import of LF cases into Europe, the United States, 
Japan, and Canada, placing local populations at risk.  
LF has an insidious onset and presents with a wide spectrum of clinical manifestations, making 
diagnosis based on clinical symptoms often difficult. The incubation period of LF is 7-18 days, 
followed by fever, weakness and general malaise. A majority of patients develop cough, headache, 
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sore throat, and gastrointestinal manifestations. Signs of increased vascular permeability such as facial 
edema and pleural effusions indicate a poor prognosis. In lethal cases, deterioration is rapid with 
progressive signs and symptoms of pulmonary edema, respiratory distress, and shock, accompanied by 
bleeding from mucosal surfaces. A highly predictive factor for disease outcome is the extent of 
viremia. Patients developing a fatal LFV infection have higher viral loads and are unable to limit 
viremia while survivors have lower viral load and clear the virus. 
The host’s control of LFV replication is primarily mediated by cellular immunity. Antibodies play a 
modest role in acute LFV infection as patients can recover in the absence of a neutralizing antibody 
response. Like in other human viral HF, hallmark of fatal LF in humans is a marked 
immunosuppression (Geisbert and Jahrling, 2004). 
Despite recent progress in the development of a LF vaccine (Fisher-Hoch, 2004; Geisbert et al., 2005), 
to my knowledge, to date no human vaccine trials have taken place. The only drug currently available 
for treatment of acute LF is the nucleoside analogue ribavirin, which significantly reduces mortality 
(McCormick et al., 1986). Since ribavirin does not neutralize free virus, it is less efficient in patients 
with high virus loads, especially late in infection. The strong predictive value of virus concentration in 
blood for a disastrous disease outcome in LF indicates a close competition between virus spread and 
the anti-viral immune response. Rapid viral dissemination critically depends on efficient 
attachment of the virus to receptor molecules on target cells and subsequent entry. Drugs able to 
block virus-receptor binding and/or entry will therefore give the host’s immune system an 
advantage by providing a wider window of opportunity for the generation of an efficient anti-
viral immune response. The development of novel anti-viral drugs targeting these early steps of 
infection appears therefore as a promising approach for better treatment of Lassa fever in 
humans. 
 
A.3 Current therapy against arenaviruses 
 
The only licensed drug against arenaviruses, which is currently available is the guanosine analogue 
ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) (Parker, 2005). In vitro and in vivo 
studies have documented the prophylactic and therapeutic value of ribavirin against several 
arenaviruses. Ribavirin has been shown to reduce significantly both morbidity and mortality in humans 
associated with LFV infection (McCormick et al., 1986). As with other nucleoside analogues, ribavirin 
is a prodrug that needs to be converted to nucleotide metabolites to exert its antiviral activity. Ribavirin 
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is phosphorylated by adenosine kinase to ribavirin monophosphate (RMP), which is then converted 
into its triphosphate form (RTP) by the successive action of mono-and di-phosphate kinases. Ribavirin 
can exerts its antiviral activity by a variety of mechanisms. RMP is a strong inhibitor of IMP 
dehydrogenase, which causes a large reduction in the intracellular levels of GTP and dGTP that can 
affect viral RNA synthesis. On the other hand RTP can interfere with the capping of viral mRNA, and 
with the function of the virus RNA-dependent RNA polymerase (RdRp). Recent evidence indicates 
that RTP can be efficiently used as substrate by the RdRp of some riboviruses, which results in C to U 
and G to A transitions. This mutagenic activity of RTP has been linked to its antiviral activity via 
lethal mutagenesis. The precise mechanisms by which ribavirin interferes with arenavirus 
multiplication remain to be determined. One of the problems associated with the use of ribavirin is that 
in a high percentage of cases (> 40%) treated individuals develop haemolytic anemia. Likewise, 
ribavirin has been associated with congenital disorders and hence it should be not used with pregnant 
women. In addition, oral ribavirin appears to be significantly less effective than the one administered 
intravenously, which pose some additional logistic complications for its use in regions with limited 
clinical infrastructure.  
Several ribavirin related inhibitors of IMP dehydrogenase, including ribamidine (1-beta-D-
ribofuranosyl-1,2,4-tiazole-3-carboxamide) (Andrei and de Clercq, 1993), as well as acyclic and 
carbocyclic adenosine analogue inhibitors of the S-adenosylhomocysteine (SAH) hydrolase (Andrei 
and de Clercq, 1990) have been show to have also anti-arenaviruses. Likewise, phenotiazines 
compounds (Candurra et al., 1996), myristic acid (Cordo et al., 1999), several disulfide-based 
compounds (Garcia et al., 2002), and brassinosteroids (Castilla et al., 2005) have been reported to have 
activity against several arenaviruses. However, apart from ribavirin, none of these compounds 
have been tested in human trials and their efficacy in vivo in currently unknown.  
Another class of compounds that showed significant anti-viral activity against arenaviruses are sulfated 
polysaccharides like dextrane sulfate, fucoidan, heparan sulfate, and heparin (Andrei and de Clercq, 
1990). These anionic polymers have anti-viral activity against a number of human pathogenic viruses, 
including HIV (Kilby and Eron, 2003) and have been studied extensively in the past decade.  Based on 
their large size and charged nature, these polymer drugs are thought to function as inhibitors of cell 
attachment and entry. In case of HIV, a direct interaction of the polymer drugs with specific sites of the 
viral GP has been demonstrated recently. 
In case of arenaviruses, the therapeutic anti-viral potential of these drugs and their mechanism of 
action are still controversial. One goal of the present study is therefore a systematic analysis of the 
anti-viral activity against human pathogenic arenaviruses of candidate anionic polymer drugs and the 
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elucidation of their mechanism of action using a panel of state-of-the art tools and assays available in 
the laboratory.  
 
A.4 Targeting arenavirus receptor binding and entry is a promising new anti-viral strategy 
 
The strong predictive value of virus concentration in blood for a disastrous disease outcome in human 
arenavirus infection indicates a close competition between virus spread and the anti-viral immune 
response. Rapid viral dissemination critically depends on efficient attachment of the virus to receptor 
molecules on target cells and subsequent entry. Drugs able to block virus-receptor binding and/or entry 
will therefore give the host’s immune system an advantage by providing a wider window of 
opportunity for the generation of an efficient anti-viral immune response. The development of novel 
anti-viral drugs targeting these early steps of infection appears therefore as a promising approach for 
better treatment of arenavirus infection in humans. 
Since binding of a virus to its cellular receptor(s) is the initial step of viral infection, it provides a 
primary target for therapeutic intervention. The feasibility of this type of approach has been 
demonstrated in the efforts to develop drugs against human immunodeficiency virus (HIV-1) 
(reviewed by Eron and Kilby, 2003). In the late 1980s, recombinant forms of the HIV receptor CD4 
have been generated that proved to be potent inhibitors for laboratory strains of HIV but failed to block 
infection with primary isolate. The recombinant receptor-derived drug PRO542 is a tetramer hybrid 
that contains the receptor domains of CD4 in a human IgG backbone and is efficacious in blocking the 
receptor binding-site on GP120 of diverse strains of HIV-1. In pilot studies, anti-viral activity was 
detected in adults and in children. Although the intravenous route of delivery and potential antigenicity 
of such receptor-decoys are of considerable concern in prolonged treatment of chronic HIV infection, 
these restrictions would not apply for similar drugs used for short-term treatment of acute arenavirus 
infection in humans. The development of receptor-based macromolecular anti-viral drugs targeting 
virus-host cell attachment represents therefore a promising approach in case of human pathogenic 
arenavirues. The identification of α-dystroglycan (α-DG) as the first cellular receptor for LFV (Cao et 
al., 1998) opens the possibility to design recombinant receptor-decoys to target the attachment of LFV 
to the host cell.  
Upon receptor binding, arenavirus virions are internalized by uncoated vesicles and released into the 
cytoplasm by a pH-dependent membrane fusion step. The pH-dependent fusion between viral and cell 
membranes represents another potential drug target. While blocking of the fusion of virus with the cell 
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membrane has not yet been evaluated as an anti-viral strategy against arenaviruses, extensive 
experience with this type of approach has accumulated in the HIV field. After binding of HIV-1 
GP120 to CD4 and the chemokine co-receptors, GP120 is thought to undergo conformational changes 
that expose gp41, the membrane-spanning portion of the HIV-1 envelope GP. Release of GP120 
propels the previously sequestered fusion peptide of gp41 outward. While the fusion peptide inserts 
into the target cell membrane, exposed hydrophobic regions in the intertwined heptad-repeats (HR2) of 
gp41 interact with the gp41 HR1 coiled coils, forming a six-helix bundle. This “trimer of hairpins” 
configuration brings the viral and the cell membrane into close proximity and allows initiation of 
membrane fusion. In the past years a number of inhibitors have been developed that target this fusion 
process, among them enfuvirtide (T-20) and T1249, peptides that prevent the formation of the six-helix 
bundle intermediate. Despite important differences in membrane fusion between arenaviruses and 
HIV-1, like e.g. different cellular locations and distinct pH requirements, targeting of the fusion 
machinery present in arenavirus GPs appears as a viable option for the development of anti-viral drugs.  
 
A.5 Small molecule inhibitors of protein interactions derived from combinatorial chemical 
libraries 
 
Although LFVGP interacts with α-DG and possible yet unknown co-receptors likely by large 
molecular interfaces, a large number of studies on receptor-ligand binding indicate that in most cases, 
small clusters of amino acid residues mediate the energetically most important interactions. This leads 
us to expect that small molecules may be capable of blocking the virus-receptor interaction. Since no 
further structural information of the target proteins are currently available, we are using a 
combinatorial chemistry approach to search for synthetic antagonists of the binding of LFVGP to its 
receptor molecule(s). This strategy has recently been used successfully to identify several 
physiologically active inhibitors of novel biochemically not yet characterized interactions (Boger et al., 
1998, Boger et al., 2000, Boger et al., 2001; Boger et al., 2003a/b, Silletti et al., 2001).  
In Dr. Dale Boger's laboratory (Department of Chemistry, TSRI), solution-phase synthetic techniques 
have been developed to create combinatorial libraries of small molecules that can be used to screen for 
and identify molecules that promote protein–protein interactions (agonists) or inhibit protein–protein 
interactions (antagonists) (Fig. A5).   
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Figure A5: Example of a combinatorial chemical library used in our studies: I a first step, imididiacetic 
acid anhydride is coupled to the aromatic primary amines (A), resulting in 6 different products. Each of the 
products is then reacted with the compounds shown in B, resulting in a total of 60 compounds containing 
permutations of A and B substituents. The 60 compounds are then reacted with a mixture of 10 dicarbocyclic 
acids shown in C, resulting in 60 mixtures of 10 compounds with the general structure shown.  
 
The multistep synthesis of such chemical libraries employing liquid–liquid and liquid–solid extractions 
to remove unreacted starting materials, reagents, and reagent byproducts provide the purified final 
products (>95% pure) irrespective of reaction efficiency. 
Implementation is in formats for the parallel synthesis of individual pure compounds (1000 member 
libraries, individual compounds) and modest sized libraries composed of small mixtures (1,000–10,000 
membered libraries, 10–50 compounds/mixture). This allows an approach to be adopted in a format 
compatible with our screening objective. Further, the compounds are not attached to solid supports 
making them immediately available for binding or functional assays. We presently have approximately 
100,000 compounds in libraries that may be screened immediately and this collection grows at a pace 
of > 20,000 compounds/year. 
Using this approach and Dr. Boger's libraries, erythropoieitin (EPO) mimetics (promote EPO receptor 
dimerization) (Goldberg et al., 2002), inhibitors of Myc/Max dimerization (Berg et al., 2002), and 
inhibitors of the binding of the protease MMP-2 to αvß3 integrin have been discovered (Silletti et al., 
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2001; Boger et al., 2001). Based on the previous success with discovery and development of these 
small molecule inhibitors of protein–protein interactions, we plan to identify effective in vitro and in 
vivo inhibitors of viral infectivity from combinatorial chemical libraries 
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B. MATERIALS AND METHODS 
 
 
B.1 Reagents and antibodies 
 
Monoclonal antibodies (mAb) 33.1 and 83.6 (anti-LCMVGP2) have been described (Buchmeier et al., 
1981; Weber and Buchmeier, 1988). The rabbit anti-GFP polyclonal Ab was from Chemicon. FITC-
conjugated anti-rabbit IgG and phycoerythrin (PE)-conjugated anti-rat IgG were from Jackson 
Immuno-Research (West Grove, PA), and the HRP-conjugated anti-mouse IgG was from Pierce 
Chemical Co. (Rockford, IL). The Steady Glo® and Bright-Glo® luciferase assay systems were 
obtained from Promega (Madison WI). Heparan sulfate and heparin were purchased from Sigma. 
 
B.2 Cell lines 
 
African green monkey kidney (Vero-E6) cells were maintained in Dulbecco’s modified Eagle medium 
(DMEM) (Gibco BRL, Grand Island, NY) containing 10% fetal calf serum (HyClone, Logan, UT). 
HEK293H cells were purchased from GIBCO BRL. For culturing as adherent cells, HEK293H were 
kept in complete serum-containing medium: DMEM, 10 % (vol/vol) FBS, supplemented with 
glutamine, and penicillin/streptomycin. For suspension cultures, cells were briefly trypsinized, washed 
twice in DMEM and re-suspended in the chemically defined serum-free medium 293 SFMII (GIBCO). 
The cell lines HeLa, A549 human lung carcinoma cells (ATCC CCL-185), and the packagic cell line 
GP293® (Invitrogen) were cultured in DMEM, 10 % (vol/vol) FBS, supplemented with glutamine, and 
penicillin/streptomycin. The glycosaminoglycan-deficient CHO cell line psgA-745 was obtained from 
ATCC. PsgA-745 cells and control wild-type CHO cells were kept in Ham’s F12K medium 
supplemented with 10 % (vol/vol) FBS and 1.5 g/l sodium bicarbonate. 
 
B.3 Virus strains, purification, and quantification  
 
Origin, passage and characteristics of LCMV ARM53b and clone-13 have been described elsewhere 
(Dutko and Oldstone, 1983). Seed stocks of all viruses were prepared by growth in BHK-21 cells. 
Purified virus stocks were produced and virus titers determined as described. LFV Josiah was grown in 
Vero-E6 cells, polyethylene glycol-precipitated and γ-inactivated at the Center for Disease Control and 
Prevention in Atlanta GA. 
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Seed stocks of Pichinde were prepared by growth in BHK-21 cells. Purified virus stocks were 
produced and titers determined as described (Dutko et al., 1983). Amapari, Parana, Oliveros, Latino, 
Guanarito, Junin, Machupo, and LFV were grown in Vero-E6 cells in a BSL4 facility, polyethylene 
glycol-precipitated and γ-inactivated as described (Elliot et al., 1982). Inactivation was verified by a 
double blind passage of the inactivated viruses on Vero E6 cells followed by immunofluoresence 
staining for detection of viral antigen.  Pichinde virus was inactivated by UV irradiation as described 
(Kunz et al., 2004). Inactivation was verified by plaque assay on Vero cells. The work with most of the 
infectious viruses was done at biosafety level 3 (BSL-3), with the exception of LFV, Guanarito, Junin, 
and Machupo viruses, which were handled in the BSL-4 laboratories at the Special Pathogens Branch, 
and Pichinde, which was handled at BSL-2 at the Scripps Research Institute. 
 
B.4 Detection of LCMVGP in ELISA 
 
Purified viruses were coated in triplicate wells in 96-well EIA/RIA high-bond microtiter plates 
(Corning) for 2 hours at 6 ºC and non-specific binding blocked with 1% (wt/vol) BSA/PBS. MAbs 
83.6 (anti-LCMVGP2) was applied in 1: 100 dilution for 2 hours at 6 ºC and detected with peroxidase-
conjugated anti-mouse IgG (1: 1000) in a color reaction using ABTS (2,2’azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid)) substrate. OD (405) was measured with an ELISA reader. For the 
determination of specific binding, background binding to BSA was subtracted.  
 
B.5 Immunoblotting 
 
Proteins were denatured in hot (95 ºC) SDS-PAGE sample buffer: 2% (wt/vol) SDS, 50 mM Tris/HCl, 
pH 6.8, 100 mM DTT. Proteins were separated by gel electrophoresis and transferred to nitrocellulose 
using precast Novex® tris-glycine gels. After blocking in 5% (wt/vol) skim milk powder in PBS, 
membranes were incubated with the primary antibody mouse monoclonal antibody M2 anti-flag in a 
dilution of 1:1000 in 2% (wt/vol) skim milk powder, PBS for 12 hours at 6 ºC. After several washes in 
PBS, 0.1% (wt/vol) Tween-20 (PBST), the secondary antibody, goat anti-mouse IgG coupled to 
peroxidase was applied 1: 5000 in PBST for 1 hour at room temperature. Blots were developed by 
enhanced chemiluminescence (ECL) using Super Signal West Pico ECL Substrate (Pierce) and signals 
were recorded on autoradiographic film (Kodak, Rochester, N.Y.). 
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B.6 Molecular biology techniques 
 
B.6.1 Polymerase chain reaction (PCR) 
PCR profile  
Segment# duration (min)  temperature (ºC)  process 
 
1  5   95    strand separation 
2*  1   95    strand separation 
3*  1   50    primer annealing 
4*  1   72    extension 
4  1   72    extension 
5  for ever  4    cool down 
 
*segments 2-4 were repeated 16 times  
 
PCR reaction mixture 
 
Reagent   final concentration   µl 
PCR water   -     39.5 
10 x pfu/taq buffer  1 x      5 
dNTPs    200 µM/nucleotid   1 
primer 1   500 nM    1.25 
primer 2    500 nM    1.25 
DNA template   500 ng     1 
Pfu/Taq-polymerase  2.5 U     1 
 
 
B.6.2 Phenol chloroform extraction 
 
Phenol chloroform extraction was performed to remove contaminating proteins from DNA. 50 μL of 
phenol chloroform was added to the DNA solution. The mixture was vortexes on full speed for 1min 
and then spun on full speed (14 krpm) for 1 min. The upper phase was transferred to a new 
eppendorphtube and added 2.5 volumes of pure ethanol. The DNA precipitated at -70°C > 30 min (or 
overnight), then spun for 15 min at 14 krpm in the cold room. Supernatant was removed and pellet 
washed with 50 μL cold (-20°C) 75% ethanol. Ethanol was removed and the pellet air-dried. The pellet 
was dissolved in PCR water (30 μL) at 37°C. The amount and quality of the DNA fragment was 
checked by gel electrophoresis. 
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B.6.3 Agarose gel electrophoresis 
 
Agarose gel electrophoresis can be used to distinguish and separate DNA fragments of different sizes. 
Small DNA fragments (<2.0 kilobases) are separated on gels with 1.0-2.0% agarose and larger DNA 
fragments (2.0-10.0 kilobases) are separated on gels with 0.6-1.0% agarose.  The DNA molecules will 
run over the gel in the electrical field, migrating toward the anode. The speed of migration of the DNA 
molecules depends on their size; therefore the small molecules will migrate faster than those of the 
larger sizes because they more readily travel through the polymer matrix. To determine the size of the 
separated DNA molecules, they are compared to a DNA marker fragments of known size run on the 
same gel. Ethidium bromide is pre added to the gel and will interchelate between basepairs of the DNA 
double helix. This will emit light (fluorescence) exposed to UV light providing a means to detect the 
location of the DNA in the gel. 
The agarose was dissolved in 100 ml 1x TAE buffer and heated to the boiling point in the microwave 
oven. 1 drop of ethidium bromide was added to the agarose and the solution was pored into a gel mold 
fitted with the appropriate comb. The gel was allowed to harden at room temperature. The comb was 
removed and the gel was transfered to an electrophoresis chamber and covered with 1x TAE buffer. 
DNA loading buffer was added to the DNA samples and they were loaded on the gel. A DNA marker 
was added in a free well. The gel was run at 120 V. The DNA was visualized under UV-light. 
 
B.6.4 Gel extraction 
 
The QIAGEN Gel Extraction Kit (QIAquick Gel Extraction Kit) was used for extraction of DNA from 
the gel. 
The DNA fragment from the agarose gel was excised with a clean, sharp scalpel and weighed in a 
colorless tube. 3 volumes of Buffer QG were added to 1 volume of gel and this was incubated at 50°C 
for 10 min (until the gel slice had completely dissolved). 1 gel volume of isopropanol was added and 
mixed with the sample. A QIAquick spin column was placed in a provided 2 ml collection tube. To 
bind DNA, the sample was added to the QIAquick column, and centrifuge for 1 min. The flow-trough 
was discarded and the QIAquick column was placed back in the same collection tube. For washing, 
0.75 ml of Buffer PE was added to QIAquick column and centrifuged for 1min. The flow-trough was 
discarded and the QIAquick column was centrifuged for an additional 1 min. The QIAquick column 
was placed into a clean 1.5 ml microcentrifuge tube. To elute DNA, 50 μL of Buffer EB was added to 
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the center of the QIAquick membrane, the column was standing for 1min, and then centrifuged for 1 
min. For gel analyze of the extracted DNA, 1 volume of Loading Dye was added to 5 volumes of 
purified DNA. The solution was mixed by pipetting up and down and then loaded to the gel. 
 
B.6.5 Treatment of DNA fragments with calf intestinal phosphatase (CIP)  
 
The removal of terminal phosphate greatly reduces re-ligation e.g. of vector DNA and is essential for 
all vector DNA intended for use in ligation reactions. After completion of the restriction digest, calf 
intestinal phosphatase (CIP) is added to the reaction. CIP is compatible wit all four NEB buffers. 
1 µl of CIP (Promega) was added to each preparative vector digest and the reaction was mixed 
thoroughly before it was incubated for 30 minutes at 37 ºC. 
 
B.6.6 Ligation of DNA fragments with T4 DNA ligase 
 
The DNA fragment and the vector DNA were separated in a preparative TAE gel. The DNA fragments 
were recovered from the gel using QIAEXII gel extraction. DNA fragments recovered by QIAEX were 
present in 20µl 1 mM Tris/HCl pH 8.0, which is ideal for subsequent ligations by T4 DNA ligase. For 
each ligation reaction, a control-reaction that contained only the vector DNA was included to assess 
the background of vector re-ligation. 
Ligase reaction 
 Component     µl 
DNA fragment (recovered by QUIAEX) 12 
 Vector DNA (recovered by QUIAEX) 5 
 10 x T4 DNA ligase buffer   2 
 T4 DNA ligase (NEB)   1 
 
Reaction times: 2-16 h at 16ºC (water bath in cold-room) 
 
B.6.7 Transformation of E.coli 
 
The following protocol was used for the transformation of chemically competent strains of E.coli like 
e.g. DH5-α: The competent bacteria were thawed on wet ice. For transformation, 50 μL bacteria were 
needed, the rest of the competent bacteria were aliquoted in 50 μL aliquots that were snap frozen (i.e. 
frozen quickly in a cold bath prepared with ethanol and dry ice). The 50 μL bacteria were mixed with 5 
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μL of the ligation reaction and kept on ice for 30min and then put at 37°C for 30 seconds (heat shock). 
The reaction was put on ice for one minute and added 1 ml of LB medium without antibiotic. The 
reactions were shaken at 180 rpm for 40-60min at 37°C and then spun in microcentrifuge 14 krpm for 
30 second. All LB medium was removed except of 50 μL of liquid so the bacteria could gently be re-
suspended. The bacteria suspention were plated on Amp/LB plates and kept at 37°C for 16-24 h. 
 
B.6.8 Plasmid DNA Purification Using the QIAprep Spin Miniprep Kit  
 
The QIAGEN Miniprep Kit is used for plasmid DNA purification from overnight cultures of E.coli 
grown in LB medium. Circa 1 ml of each sample bacteria suspention was transfered to tubes, spun for 
1min at 14 krpm. The supernatant was discarded and the pelleted bacterial cells were resuspended in 
250 μL Buffer P1. 250 μL Buffer P2 was added to the tubes and mixed thoroughly by inverting the 
tubes gently 4-6 times. 350 μL Buffer N3 was added to the tubes and mixed immediately and 
thoroughly by inverting the tubes 4-6 times. The tubes were centrifuged for 10 min at 13 krpm in a 
table-top microcentrifuge. The supernatant from this last step was applied to the QIAprep spin column 
by decanting or pipetting. The columns were then centrifuged 60 s and the Flow-through were 
discarded. 
For washing, 0.75 ml Buffer PE was added to the QIAprep spin columns before they were centrifuged 
for 60 s. The flow-through was discarded and the columns were centrifuge for an additional 1 min to 
remove residual wash buffer. The QIAprep columns were placed in a clean 1.5 ml microcentrifuge 
tubes. To elute DNA, 50 μL Buffer EB was added to the center of each QIAprep spin column. The 
columns were standing for 1 min before centrifugation for 1 min.  
 
B.7 Generation of pseudotyped retroviral vectors  
 
The packaging cell line GP2-293® from BD Bioscience stably expresses the Moloney mouse leukemia 
virus (MLV) derived gag and pol gene and allows packaging of any MMLV-based vector containing 
the appropriate packaging signal. 
 
Co-transfection of a MLV-derived retroviral genomic plasmid pLZRS-Luc-gfp and the GP 
expression plasmid: GP2-293 cells were cultivated on plastic in T175 flasks to a confluency of 80%. 
The cells were split 1:2 into T175 flasks coated with poly-L-lysine. Medium for maintenance and 
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transfection: DMEM, 10% (v/v) FBS, Gln, P/S. Medium for virus production: DMEM, 10% (v/v) FBS, 
Gln, P/S, 20 mM Hepes. Transfection was carried out according to Sonderegger et al., Curr. Prot. Cell 
Biol. Unit 9.5. Briefly, 4 h prior to transfection, medium was removed and 40 ml of fresh medium was 
added per flask. Solution A was prepared (2 ml 0.25 M CaCl2, 20 µg GP expression plasmid DNA 
(QiaGen Maxi-prep), 20 µg MLV genomic plasmid pLZRS-Luc-gfp DNA (QiaGen Maxi-prep)). 
Solution A was mixed into solution B (2 ml HBS) and incubated at room temperature for exactly 1 
min. Transfection solution was added to cells and distributed evenly. Flasks were incubated at 37ºC, 
5% CO2 for 4-12 h. Transfection mix was removed and cells were washed twice with medium. 
Complete medium with 20 mM Hepes was added (25 ml/ flask) before the flasks were put back in the 
incubator. The pseudotypes were harvested after 24 and 48 hours, cleared by low speed centrifugation 
and frozen at –70ºC. 
 
B.8 Infection of human cells with retroviral pseudotypes  
 
Target cells: One day before the assay 2 x 104 HeLa cells were plated per well in flat bottom M96 
plates (total volume medium 200 µl) in DMEM, 10% FBS, Gln, non-essential amino acids, Pen/Strep. 
The cells were circa 80% confluent at time of assay (after 16-24 hours). 
 
Infection: Medium from target cells was removed, 100 µl pseudotypes was added to cells before they 
were incubated for 1 h at 37ºC, 5% CO2. Mixture was removed and cells were washed twice with 
DMEM, 10 mM Hepes without FBS. 100 µl complete medium containing 10 mM Hepes per well were 
added and cells were incubated for 40-48 h at 37ºC, 5% CO2. The results were read by Steady-Glo® 
luciferase assay. 
 
B.9 Steady-Glo® luciferase assay 
 
The Steady-Glo® luciferase assay is fully compatible with our medium (DMEM with 10 % FBS). The 
presence of phenol red reduced the signal intensity by circa 30%. We will avoid this problem in the 
future by using medium without phenol red. 
The old medium was removed from the cells and replaced with 100 µl/well of fresh (37 ºC warm) 
medium. 100 µl assay (room-temperature) reagent/well were added to the plates. After 5 minutes, the 
cells were scratched off from the bottom of the plate and mix well with the solution (> 5 times up and 
down pipetting). Content of wells were transferred into a white M96 plate suitable for 
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chemiluminescence reader. Luminescence was measured in a 96-well plate luminometer (Bertold) 
using WinGlow software. 
 
B.10 Screening of chemical libraries: inhibition of the infection with retroviral pseudotypes by 
compounds from combinatorial chemical libraries 
 
Compound mixtures: The compound mixtures derived from combinatorial chemical libraries were 
dissolved in DMSO, in a concentration of 5 mM. We had 10 µl per compound mixture. The libraries 
were provided in 96 well plate formats. The pharmacologically active concentration in the primary 
screening assay, ideally 50 µM, corresponded to a 100-fold dilution of the stocks. 
 
Pseudotypes: Retroviral pseudotypes containing the GPs of different arenaviruses (LFV, LCMV, 
Amapari, Guanarito, Junin, Machupo, and Vesicular stomatitis virus,) produced as described, were 
used in this assay.  
 
Target cells: One day before the assay 2 x 104 HeLa cells were plated per well in flat bottom M96 
plates (total volume medium 200 µl) in DMEM, 10% FBS, Gln, non-essential amino acids, Pen/Strep. 
The cells were circa 80% confluent at time of assay (after 16-24 hours). 
 
Blocking pseudotypes with compounds: For the screening assay, exact replicas of the plates were 
done to avoid mix-up of samples. Empty wells of the compound plate were used for controls. 100 µl of 
pseudotypes in OPTIMEM, 2% FBS, 10 mM Hepes were added per well of a M96 plate and 1 µl of 
compound mixture were added per well and mixed briefly. For control wells DMSO only were added. 
Plates were incubated for one hour on ice. 
 
Infection: Medium from target cells were removed and 80 µl of pseudotypes /compound mixtures 
were added to each well before plates were incubated for 1 h at 37ºC, 5% CO2. After incubation, 
mixtures were removed and cells were washed once with DMEM, 20 mM Hepes without FBS. 100 µl 
complete medium containing 20 mM Hepes were added per well and plates were incubated for 40-48 h 
at 37ºC, 5% CO2. The results were read by Steady-Glo® luciferase assay. 
 
 
 
 20
Materials and methods 
B.11 Target-specificity of compound mixtures 
 
To assess the target-specificity of compound mixtures derived from combinatorial chemical libraries, 
compound mixtures were tested for their ability to block infection of target cells with arenavirus 
pseudotypes but not with pseudotypes containing the GP of the unrelated VSV. This was done by 
using the assay described in B9. 
 
B.12 Determination of the dose-response characteristics of selected candidate compounds  
 
Cells: Human lung epithel A549 in DMEM/10% FBS/Gln/PS 
One day before the assay 2 x 104 cells were plated per well in flat bottom M96 plates (total volume 
medium 200 µl). At the time of assay, the cells were circa 80% confluent (after 16-24 hours). 
 
Blocking of LFV-PS/VSV-PS with increasing concentrations of candidate compounds: 
 
Concentration µl LFVPS  µl compound  dilution 
 
0   300   6   pure DMSO 
1 µM   300   6   50 µM (1:100) 
5 µM   300   5   500 µM (1: 10) 
10 µM   300   6   500 µM (1:10) 
20 µM   300   1.2   5 mM (stock) 
50µM   300   3   5 mM (stock) 
100 µM  300   6   5 mM (stock) 
 
Infection in triplicates: Medium was removed from target cells, 90 µl of PS /compound mixtures 
were added to cells and plates were incubated for 1 h at 37ºC, 5% CO2. After incubation, mixture was 
removed and cells were washed once with DMEM, 10 mM Hepes without FBS. 100 µl complete 
medium containing 10 mM Hepes was added per well and plates were incubated for 40-48 h at 37ºC, 
5% CO2. The results were read by Steady-Glo® luciferase assay. 
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B.13 Blocking of pseudotype infection with sulfated polysaccarides  
 
Dextran sulfate and fucoidan stock solutions: 10 ml of solution of 10 mg/ml in 400 mM Hepes, pH 
7.5 were prepared and filtered through 0.45 µM filter.  
 
Target cells: One day before the assay, 2 x 104 Vero cells were plated per well in flat bottom M96 
plates (total volume medium 200 µl) in DMEM, 10% FBS, Gln, non-essential amino acids, Pen/Strep. 
At the time of assay, the cells were circa 80% confluent (after 16-24 hours). 
 
Retroviral pseudotypes: LFV, Guanarito, Junin, Machupo, VSV were done in triplicate samples, 
added 100 µl of pseudotypes per well. 
 
Blocking of pseudotypes with dextran sulfate or fucoidan: Compounds were added to the 
pseudotypes according as follows: 
HS/heparin (µg/ml) µl pseudotypes µl PCM µl HS/heparin stock 
0   360   40  0 
0.2   360   32  8 (10 µg/ml stock) 
1   360   0  40 (10 µg/ml stock) 
5   360   38  2 (1 mg/ml stock) 
25   360   30  10 (1 mg/ml stock) 
100   360   0  40 (1 mg/ml stock) 
 
Infection: Medium from target cells were removed and 100 µl of the pseudotype mix were added to 
each well and incubated for 1 h at 37ºC, 5% CO2. After incubation, mixture was removed and cells 
were washed once with PCM, 20 mM Hepes. 200 µl PCM containing 20 mM Hepes were added per 
well and incubated for 40-48 h at 37ºC, 5% CO2. The results were read by Steady-Glo® luciferase 
assay. 
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B.14 Intracellular FACS staining for LCMV-NP using mAb 113  
 
Preparation of a single cell suspension: The cells cultivated in 6 well plates were washed twice with 
PBS. 1 ml/well of Trypsin-EDTA were added to the cells but not removed completely, leaving some 
liquid left in each well. The plates were incubated at 37ºC for 5 minutes, the cells were detach by 
slapping against the plate and re-suspend in 1ml/well 1% FBS/PBS. The cell-suspension were 
transferred to 5 ml polystyrene tube and kept on ice. The tubes were spun 1600 rpm/4min/4oC and 
supernatant was removed. Cells were re-suspend in 2 ml of 1% FBS/PBS. The tubes were again spun 
1600 rpm/4min/4oC and supernatant was removed. The cells were re-suspend in 250 µl of 1% 
FBS/PBS and kept on ice. 200 µl of each cell-suspensions were transferred into a M96 plate with 
conical wells. 
 
Fixation and permeabilization: The cells were spun down 1600 rpm/4min/4oC and supernatant were 
removed. Cells were resuspended in 100 µl/well of 4% (w/v) PFA/PBS and kept at RT for 10 min. The 
cells were washed twice with 1% (v/v) FBS/0.1% (w/v) saponin/PBS. 
 
Wash procedure: The cells were spun down 1600 rpm/4min/4oC and re-suspend in 200 µl/well of 1% 
(v/v) FBS/0.1% (w/v) saponin/PBS. 
 
Intracellular staining with mAb 113 anti LCMVNP: mAb 113 was diluted 1: 100 in 1% (v/v) 
FBS/0.1% (w/v) saponin/PBS. Cells were resuspended in 100 µl/well of Ab solution and incubated for 
45 minutes on ice in the dark. Cells were wash twice with 1% (v/v) FBS/0.1% (w/v) saponin/PBS. 
 
Detection with FITC-conjugated 2nd Ab: 2nd Ab anti-mouse IgG F(ab)2-FITC was diluted 1: 100 in 
1% (v/v) FBS/0.1% (w/v) saponin/PBS. Cells were re-suspend in 100 µl/well of 2nd Ab and incubated 
for 45 minutes on ice in the dark. After incubation, the cells were washed once with 1% (v/v) 
FBS/0.1% (w/v) saponin/PBS and twice with 1% FBS/PBS. Cells were re-suspend in 200 µl/well PBS 
and kept in the dark.  
 
B.15 Detection of LCMV-NP by immunofluorescence staining 
 
Cells: 104 Vero E6 cells were plated per well of a 8 well LabTek tissue chamber slides (Nunc) and 
cultured over night. 
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Infection with LCMV: LCMV was added at MOI of 0, 0.01, 0.1, and 1 in an inoculum of 250 µl 
medium for 45 minutes at 37ºC, 5% CO2. After infection, cells were washed and 0.5 ml fresh medium 
per well were added.    
 
Fixation of cells: The culture medium was removed and 250 µl of 2% formaldehyde/0.1% 
glutaraldehyde in PBS (room temperature) was added to each well for fixation of the cells at 37oC for 
15 minutes in the dark. The formaldehyde fixative was aspirated and cells were washed twice with 
PBS. PBS was removed after the second wash step and 500 µl PBS/1% (v/v) FCS were added and cells 
incubated for 15 min at room temperature. 
 
Immunofluorescence staining 
 
Permeabilization of cells: After the blocking step (#2), 250 µl PBS/1% (v/v) FCS/0.1% (w/v) saponin 
was added and cells incubated for 15 min at room temperature.  
 
Incubation with primary antibody: Primary antibody: mAb 113 anti-LCMVNP 1: 200 in PBS/1% 
(v/v) FCS/0.1% (w/v) saponin (250 µl/well) was added and cells incubated for 1h at room temperature. 
 
Incubation with secondary antibody: The secondary antibody (goat anti mouse IgG FITC labeled) 
was diluted 1:100 in PBS/1% (v/v) FCS/0.1% (w/v) saponin. Primary antibody solution was removed 
and cells were washed 2 times with PBS. 200 µl/well secondary antibody in PBS/1% (v/v) FCS were 
added and cells were incubated for 45 min at room temperature, protect from light. Secondary antibody 
solution was removed and cells were washed 3 times with PBS. 
 
Evaluation: Fluorescence microscope with the 5x objective was used for evaluation.  All NP+ cells 
were counted and cell clusters were scored as one infection event. 
 
 24
Results 
C. RESULTS 
 
C.1 Discovery of novel small molecule inhibitors of Lassa fever virus (LFV) infection from 
combinatorial chemical libraries: 
 
C.1.1 Production and characterization of retroviral pseudotypes 
 
Since LFV is a BSL4 pathogen, studies with live virus are restricted to BSL4 laboratories. To discover 
small molecule drugs that can block the infection of human cells with LFV, our laboratory has 
generated retroviral vectors that contain the glycoprotein (GP) of LFV in their envelope. The principle 
behind this is the fact that enveloped viruses can incorporate heterologous viral GPs into their lipid 
membranes during budding. These so-called “pseudotypes” acquire the receptor specificity of the virus 
from which the heterologous GP was derived. 
Using the strategy outlined in Fig. C1A, we inserted the GPs of LFV strain Josiah and the LCMV 
isolates ARM53b (ARM) and clone-13 (cl-13) into virions of recombinant Moloney leukemia virus 
(MLV), which contain a luciferase and a green fluorescent protein (GFP) reporter gene. In addition, we 
generated pseudotypes containing the GPs of the New World arenavirus Amapari (AMA) and of 
vesicular stomatitis virus (VSV), which do not use α-DG as a receptor (Cao et al., 1998; Spiropoulou 
et al., 2002).  
The packaging cell line GP2-293-Luc® (BD Biosciences) stable expresses MLV gag and pol. The cells 
were transfected with a plasmid expressing a packable MLV genome pLZRS-Luc-GFP and an 
expression plasmid for LFVGP. pLZRS-Luc-GFP was developed by the laboratory of Dr. Gary Nabel 
(Yang et al., 1998) and contains a luciferase transgene and a green fluorescence protein (GFP) reporter 
encoded in a bicistronic mRNA. This guarantees a defined ratio of luciferase and GFP being expressed 
in cells transduced with the recombinant retrovirus. For transfection, I used calcium phosphate, a 
technique that results in high efficiencies of transfection. In this method, the formation of the DNA-
containing calcium phosphate particles is initiated under defined chemical conditions, in the absence of 
cells or serum. The particle size is the most critical parameter regarding efficiency of transfection, that 
is uptake of DNA-containing calcium phosphate particles by the cell. The main determinations of 
particle size are calcium and phosphate concentration, the concentration of the DNA, size of the DNA 
fragments involved, pH, temperature and time of incubation. After initial formation of the DNA-
containing calcium phosphate particles, the precipitate is added to the cells. During the incubation of 
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the precipitate with the cells, the formation of DNA-containing calcium phosphate particles continues 
and preexisting particles grow in size. The particles adhere to the cells and are taken up by 
endocytosis. After a few hours of exposure, the medium is changed and the cells start to express the 
recombinant pseudotypes. The pseudotypes are released from the cells and accumulated in the cell 
supernatant. After 48 hours, supernatants were harvested, centrifuged at low speed to remove cell 
debris, aliquoted and frozen at –80 ºC.  
The titers of the pseudotypes were determined by infection of Vero cell monolayers, using the GFP 
reporter. Briefly, serial dilution of pseudotypes were made and put on monolayers of Vero cells in 96 
well plates. After one hour of incubation, cells were washed and fresh medium added. After 48 hours, 
the cells were fixed with 2% formaldehyde and immunostaining for GFP performed using a specific 
antibody to GFP. Clusters of green cells were counted and scored as infectious uints (iu). 
Representative titers for arenavirus pseudotypes are 1-4 x 105 infectious particles per ml (iu/ml) and of 
VSV pseudotypes (VSV-PS) 5-10 x 105 iu/ml. Infection of permissive cells was reliably detected by 
luciferase assay (Fig. C1B) 
An initial characterization of the pseudotypes has already been done in the lab before I arrived. 
Although not part of my own work, the main results are displayed Fig. C1 (C and D). As can be seen, 
the arenavirus pseudotypes were specifically recognized by the monoclonal antibody (mAb) 83.6, 
which binds to a highly conserved epitope in arenavirus GP2 (Weber and Buchmeier, 1988) (Fig. 
C1C). This proofs that the GP of the heterologous virus was efficiently incorporated into the MLV 
particles during budding.  
Infection of cells by pseudotypes containing the GPs of LFV (LFV-PS), LCMV (LCMV-PS), and 
AMA (AMA-PS) was specifically blocked by the corresponding inactivated viruses, but not by 
inactivated Parana virus (PAR), an unrelated arenavirus, which belongs to the Clade A New World 
arenaviruses (Fig. C1D). Inactivated LFV, AMA, and PAR were provided by the Special Pathogens 
Branch at the Center of Disease Control in Atlanta, GA as described (Spiropoulou et al., 2002).  
These data indicate that the retroviral pseudotypes adopt the receptor binding specificities of the 
viruses from which their GPs were derived. 
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Figure C1: Recombinant retroviral vectors pseudotyped with arenavirus GPs. (A) Production of 
pseudotyped retroviruses: The packaging cell line GP2-293® (BD Biosciences) stable transfected with MLV 
gag and pol, is co-transfected with a plasmid containing the packable MLV genome pLZRS-Luc-Gfp (Yang et 
al., 1998), which contains a luciferase and a GFP reporter, and an expression plasmid for the heterologous GP 
(pC-AVGP). Retroviral pseudotypes are released into the cell supernatant. Infection of target cells results in the 
integration of the retroviral genome into the host cell DNA and can be quantified by detection of the luciferase 
or GFP reporter. (B) Infection of cells with retroviral pseudotypes: Supernatants containing pseudotypes were 
used to infect monolayers of Vero cells in 96 well plates. After 48 h, infection was quantified using the Steady-
Glo® luciferase reporter gene assay (Promega) in a Berthold 96 well-plate luminometer. Luminescence is 
expressed as fold-increase over uninfected controls (n = 3 + SD). (C) Binding of mAb 83.6 to pseudotypes:  
Equal amounts of concentrated pseudotypes containing the GPs of LCMV ARM53b (ARM), cl-13, LFV, AMA, 
and VSV were immobilized in microtiter plates and probed with mAb 83.6 anti-LCMVGP2. Primary antibodies 
were detected with POD- conjugated anti-mouse IgG in a color reaction using ABTS substrate. OD (405) was 
measured using an ELISA reader (n = 3 + SD). (D) Blocking of arenavirus pseudotype infection by inactivated 
viruses: HEK293 cells cultured in 96-well plates were blocked with inactivated LCMV (ARMi, cl-13i), LFV 
(LFVi), AMA (AMAi), or PAR (Pari) at the indicated ratios of inactivated virus particles per cell.  After 
blocking for two hours at 4 ºC, cells were infected with the indicated pseudotypes at a multiplicity of infection 
(MOI) = 1. Infection was assessed by luciferase assay as in (B) (n = 3, + SD).  
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C.1.2 Screening of combinatorial chemical libraries 
 
The Combinatorial chemical libraries were given to us by the laboratory of Dr. Dale L. Boger 
(Department of Chemistry, Scripps). The libraries were provided in 96 well plates containing either 
individual compounds or mixtures of 4-10 compounds in a concentration of 5 mM in DMSO. The 
compounds/compound mixtures were screened for their ability to block infection of target cells by 
retroviral pseudotypes that contain LFVGP in their envelope and a luciferase reporter gene.  
For each library, two independent screenings were performed as shown in Fig C2 and only 90 
compounds that showed >50% inhibition of infection in both independent screens were considered 
candidates to be followed up. During my time in the laboratory, I have screened 13 complete libraries 
with total > 10, 000 iminodiacetic acid-based and pyrrolidine-based peptidomimetic compounds. 
Duplicate screening resulted in the identification of circa 4-5% compounds/mixtures that showed 
reproducible reduced LFV-PS infection by > 50%.    
 
Figure C2: Example of the high-throughput screening of a combinatorial chemical library for inhibitors 
of LFV-PS infection. LFV-PS were pre-incubated with compound mixtures (concentration = 50 µM for 
individual compounds and 5 µM for individual compounds in mixtures of 4-10) for 45 minutes and then added 
to monolayers of HeLa cells in 96 well-plates. After one hour, the inoculum was removed, cells washed and 
incubated for 48 h. Infection was quantified using the Steady-Glo® high sensitivity luciferase reporter gene 
assay (Promega) in a Berthold® 96 well-plate luminometer. Data shown are two completely independent 
experiments screening the same library (#19). Luminescence is expressed as fold-increase over background.  
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A1-10, B1-10, C1-10, D1-10, E1-10, F1-10, and G1-10 (black bars) represent mixtures of seven different 
compounds each. The samples labeled C (white bars) correspond to solvent only controls. 100% and 50% of 
mean control values are indicated as horizontal lines. The mixtures B1-B9, which result in >50% inhibition of 
LFV-PS infection in both screens (underlined), showed the best effect for inhibition. 
 
C.1.3 Determination of the target specificities of candidate compounds 
 
Next, we wanted to select for compounds that specifically block LFVGP-mediated attachment and 
entry but do not influence subsequent steps of our retroviral pseudotype-based assay. To this end, we 
compared the effect of our 125 remaining candidate compounds/mixtures on infection with LFV-PS 
with infection with pseudotypes containing the GP of vesicular stomatitis virus (VSV-PS). VSVGP is 
structurally unrelated to LFVGP and binds to a different receptor. Our counter-selection is based on the 
fact that compounds, which specifically block LFVGP-mediated infection, should not interfere with 
VSV-PS infection while compounds that affect subsequent steps of the assay would reduce reporter 
gene expression in both, LFV-PS and VSV-PS. Determination of target specificity (Fig. C3) revealed 
that most compounds specifically reduced infection with LFV-PS but not VSV-PS.  
 
Figure C3: Determination of target specificity of representative candidate compounds/mixtures that 
showed significant blocking of LFV-PS infection in the screening assay: LFV-PS and VSV-PS were pre-
incubated with compound mixtures as in Fig. C2 and then added to monolayers of HeLa cells in 96 well-plates. 
After one hour, the inoculum was removed, cells washed twice with DMEM and incubated with fresh medium 
for 48 h. Infection was quantified using the Steady-Glo® high sensitivity luciferase reporter gene. Data shown 
are triplicates (+/- SD). The samples labeled DMSO correspond to solvent controls.  
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C.1.4 Validation of candidate compounds in different human and primate cells 
 
My own screens together with those done by other people of > 50, 000 compounds resulted in the 
identification of 157 (4.5%) compounds/mixtures that showed reproducible reduced LFV-PS infection 
by > 50%. When tested for cytotoxicity using 7-amino-actinomycin, a fluorescent dye that stains dead 
or damaged cells, most compounds/mixtures (125/147) derived from iminodiacetic acid-based and 
pyrrolidine-based peptidomimetic libraries showed no or only mild toxicity, while heterocyclic 
compounds (10/10) turned out to be toxic. Determination of target specificity (see Fig. C3 for 
representative examples) revealed that 32 single compounds and 53 compound mixtures out of a total 
of 125 specifically reduced infection with LFV-PS but not VSV-PS.  
A selection of 17 single candidate compounds was then tested for their ability to specifically block 
LFV-PS infection in a series of susceptible human and primate cell lines including HeLa, A549, and 
VeroE6 cells. The majority of candidate compounds showed consistent blocking of LFV-PS infection 
in all cell lines tested (Fig. C4), indicating that the anti-viral activity was independent of the specific 
target. 
 
Figure C4: Activity of selected candidate compounds in different cell lines:  Selected candidate compounds 
were tested for their ability to specifically inhibit LFV-PS infection in the susceptible human cell lines HeLa and 
A549 and the primate cell line VeroE6. LFV-PS and VSV-PS (negative control) were pre-incubated with the 
compounds at 50 µM and the added to cell monolayers. Infection was determined by luciferase assay. As can be 
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seen, of the 17 compounds tested in the different cell lines only eight showed highly consistent activity in all cell 
types: 7B5, 8C1, 16G8, 17C8, 17C9, 21A3, 31B7 and 31B8. The other ones, in particular compounds derived 
from library #38 showed different activities in different cell lines. While all compounds were highly active in 
HeLa cells, the cell type used for screening, some of the compounds showed only weak inhibition in A549 cells. 
The reasons for these discrepancies are not fully understood, but a possible explanation will be given later on in 
the discussion of my work. 
 
C.1.5 Dose-response curves of candidate compounds 
 
A next important step was the determination of the dose-response curves of the individual compounds. 
For this I focused on the eight candidate compounds, 7B5, 8C1, 16G8, 17C8, 17C9, 21A3, 31B7 and 
31B8, that showed the best results when tested on the different cell lines (Fig. C4). LFV-PS were pre-
incubated with increasing concentrations of compound mixtures for 1 hour and then added to 
monolayers of human lung epithelial A549 cells in 96 well-plates. After one hour, the inoculum was 
removed, cells washed and incubated for 48 h. Infection was quantified using the Steady-Glo® high 
sensitivity luciferase reporter gene assay (Promega) in a Berthold® 96 well-plate luminometer. Each 
concentration of the different compounds was done in triplicates. The dose response curves are given 
in Fig. C5. 
 
C.1.6 Determination of the activity of candidate compounds against other human pathogenic 
arenaviruses 
 
Apart from LFV, the arenavirus family contains other important human pathogens, such as the South 
American hemorrhagic fever viruses Guanarito, Junin, and Machupo. We therefore wanted to see if 
our candidate compounds that were active against LFV were also able to inhibit the infection of human 
cells with these viruses. To study the anti-viral activity of our compounds against the South American 
hemorrhagic fever viruses under BSL2 conditions, we used retroviral vectors that contain the 
glycoproteins (GPs) of Guanarito, Junin, Machupo, and the non-pathogenic New World arenavirus 
(NWAV) Amapari following the strategy used for the production of LFV pseudotypes (Fig. C1). The 
results of the original characterization done by Ms. Jillian Rojek in the lab are shown in Fig. C6. 
Briefly, infection of susceptible cells was detected using the luciferase reporter present in the retroviral 
genome (Fig. C6A). Infection of cells by pseudotypes was specifically blocked by the corresponding 
inactivated viruses, but not by inactivated LFV (Fig. C6B).  
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Figure C5: Determination of the dose-response curves for 9 selected candidate drugs. LFV-PS were pre-
incubated with increasing concentrations of compound mixtures for 1 hour and then added to monolayers of 
human lung epithelial A549 cells in 96 well-plates. After one hour, the inoculum was removed, cells washed and 
incubated for 48 h. Infection was quantified using the Steady-Glo® high sensitivity luciferase reporter gene 
assay (Promega) in a Berthold® 96 well-plate luminometer.  
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Figure C6: Recombinant retroviral vectors pseudotyped with NWAV GPs. (A) Infection of cells with 
retroviral pseudotypes: Undiluted supernatants of pseudotypes were added to monolayers of HeLa cells in 96 
well-plates and infection quantified after 48 hours using luciferase reporter gene assay. Luminescence is 
expressed as fold-increase over noninfected control cells (n = 3 + SD). (B) Blocking of New World arenavirus 
GP pseudotypes (NWAV-PS) infection by inactivated viruses: HEK293 cells cultured in 96-well plates were 
blocked with γ-inactivated Amapari (AMAi), Junin (JUNi), Guanarito (GUAi) or LFV (LFVi) at the indicated 
ratios of inactivated virus particles/cell. After incubation for two hours at 4 ºC, cells were infected with either 
NWAV pseudotypes or pseudotypes containing VSVGP (VSV-PS) at a multiplicity of infection (MOI) = 1. 
Infection was assessed after 48 h by luciferase assay (n = 3, + SD).  
 
The 17 selected candidate compounds were tested for their ability to block the infection of human cells 
(A549) with retroviral pseudotypes containing the GPs of Guanarito, Junin, and Machupo. To ensure 
the specificity of the observed reduction in infection by the candidate drugs, we used VSV pseudotypes 
as a negative control. Interestingly, many compounds that showed activity against LFV pseudotype 
infection were also active against the South American HF viruses (Fig. C7).  
Many of the candidate compounds that showed specific activity against LFV-PS showed significant 
activity against pseudotypes of Guanarito, Junin and Machupo. The responses to the compounds in the 
different NWAV-PS are very similar. In particular the compounds 16G8, 17C8 and 17C9 showed 
nearly full neutralizing potential against these pseudotypes. The NWAV-PS are all over a bit more 
sensitive for neutralizing than the LFV-PS, otherwise the NWAV-PS respond more or less consistent 
to how the LFV-PS respond to the compounds. 
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Figure C7: Activity of candidate compounds against retroviral pseudotypes of Guanarito, Junin, and 
Machupo. Candidate compounds were tested for their ability to specifically inhibit infection in the susceptible 
human cell line A549. Retroviral pseudotypes of Guanarito, Junin, and Machupo and vesicular stomatitis virus 
(VSV) (negative control) were pre-incubated with the compounds (50 µM) for one hour and then added to cell 
monolayers. Infection was determined by luciferase assay after 48 hours (n = 3 + SD). 
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C.2 Discovery of novel small molecule inhibitors of Lassa fever virus (LFV) infection from 
natural product libraries: 
 
During the past twenty years, several research groups have tested synthetic and natural compounds for 
activity against arenaviruses and found some anti-viral activity. Trifluroperazine (TFP) and 
chlorpromazine (CPZ), two pharmacologically active phenothiazine derivates, were found to be active 
on the replication of the arenaviruses Junin, Tacaribe virus and Pichinde virus (Candurra et al., 1996). 
Two myristic acid analogs (DL-2-hydroxymyristic acid (2OHM) and 13-oxamyristic acid (13OM) 
showed to have effects on Junin virus replication (Cordo et al., 1999). Ribavirin triphosphate (RTP) 
can interact with various viral RNA polymerases and inhibit virus replication (Parker, 2004). Synthetic 
brassinosteriod ((22S,23S)-3ß-bromo-5α,22,23-trihydroxystimastan-6-one) has an antiviral mode of 
action against Junin virus replication by preventing the synthesis of full length antigenomic RNA 
(Castilla et al., 2005). 
Since some of the compounds that show anti-viral activity like, hydroxymyristic acid, ribavirin 
triphosphate, and brassinosteriods are natural products or derivatives thereof, we decided to perform a 
broad screen of natural products for anti-viral activity. For this purpose, we used a natural product 
library of 2, 000 defined and characterized natural compounds. The compounds were provided by the 
Department of Chemistry at Scripps. The library was set up as 200 mixtures of 10 compounds each in 
a concentration of 500 µM per compound in DMSO. In contrast to the combinatorial chemical libraries 
used in our small molecule screens described above, the individual compounds present in the mixtures 
of this library have no structural relatedness. The natural compounds are tested for inhibition for cell-
receptor binding and/or entry.  
 
C.2.1 Screening of natural product libraries 
 
Screening of natural product libraries was done in the same way as for the combinatorial chemical 
libraries, but in addition to LFV-PS we tested the compounds for effect on Guanarito, Junin, and 
Machupo pseudotypes. Initial screening of the three natural product libraries N1-N3 resulted in the 
identification of a number of compound mixtures (with 10 compounds each) that significantly reduced 
infection of human cells with either LFV or Machupo virus pseudotypes. To select for compounds that 
block specific one of the respective psudotypes-mediated attachment and entry but do not influence 
subsequent steps of our retroviral pseudotype-based assay, we compared the effect of our candidates 
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on infection with LFV-PS with infection with pseudotypes containing the GP of vesicular stomatitis 
virus (VSV-PS).  
When we tested the active mixtures of natural compounds for target specificity using infection with 
VSV pseudotypes as a control, most mixtures showed activity also against VSV-PS (Fig. C8). Out of 
the 23 active compound mixtures tested, the mixtures N1B3, N1E5, N1G5, N1D6, N2A1, N2G8, 
N3D2 and N3F2 showed specific activity against LFV or Machupo, but not VSV.  
 
Figure C8: Target specificity of candidate mixtures derived from natural product libraries. Candidate 
mixtures from natural product libraries (10 compounds, 50 µM each) were pre-incubated with LFV-PS, 
Machupo pseudotypes and VSV-PS for one hour on ice and then added to HeLa cells. Infection was assessed 
after 48 h by luciferase assay (n = 3 + SD). 
 
C.2.2 Deconvolution of compound mixtures 
 
To identify the active compounds in each mixture, we re-screened the individual compounds present 
for their activity. This process called “deconvolution” allows the identification of the most active 
compounds in a pharmacologically active mixture (Fig. C9). The deconvoluted compounds 
(concentration of 5 µM per compound) were pre-incubated with the different pseudotypes one hour on 
ice, and infection assay carried out as described before.  
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Figure C9: Deconvolution of candidate compound mixtures derived from natural product libraries. 
Individual compounds (50 µM each) were preincubated with the indicated pseudotypes and then added to HeLa 
cells. Infection was determined as in Fig. C2. Data shown are single measurements and represent one out of two 
experiments. The candidate marked with * showed cytotoxicity on the cells. 
 
The results clearly show which compounds are specific and which ones are not. Notably, most 
compounds showed no activity when deconvoluted. In some mixtures, it was not possible to identify 
individual compounds responsible for the observed anti-viral activity of the mixture. I other cases, one 
or two compounds were found to have a significant effect while the rest did not. Notably, in one case, 
we found that although the mixture showed specificity against arenaviruses but not VSV, two 
individual compounds seem to have broader activity, also neutralizing VSV.   
 
C.3 Evaluation of polyanionic compounds as anti-arenaviral drugs 
 
Polyanionic compounds have been evaluated as very potent anti-viral drugs against arenaviruses, they 
were found to be selective inhibitors, whereas the compounds were not inhibitory to cell growth. 
Dextran sulfate, fucoidan and heparin were active at concentrations of 0.1-2.8 µg/ml and not cytotoxic 
up to a concentration of 400 µg/ml. At concentrations below the cytotoxicity threshold (inhibition of 
host cell DNA synthesis), the compounds inhibited the growth of Junin virus in Vero cells, as 
measured at 24, 48 and 72 hours after infection. The mechanism of action of these compounds was 
thought to be due to the inhibition of virus binding to the host cells (Andrei and de Clercq, 1990). 
 
C.3.1 Selection of candidate polymers: heparin, HS, DS and fucoidan 
 
Glycosaminoglycans (GAGs) are long unbranched polysaccharides containing a repeating disaccharide 
unit. GAGs are highly negatively charged molecules, with extended conformation that imparts high 
viscosity to the solution. GAGs are located primarly on the surface of the cell or in the extracellular 
matrix. Many viruses utilize GAGs, predominantly heparan sulfate (HS) as receptor or co-receptors, 
together with other molecules. Heparin and heparan sulfate (HS) are both GAGs of physiological 
significance. Heparin is a modified (higher sulfated) version of HS and is more potent than HS. 
Heparin is mainly found as a component of intacellular granules of mast cells lining the arteries of the 
lungs, liver and skin. HS contains higher acetylated glucosamine than heparin and is mainly localized 
at basement membranes as components of cell surfaces. If a virus uses HS as a receptor or co-receptor, 
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their surface glycoproteins (GPs) must contain binding sites for HS. Herpes type 1, herpes type 2, 
pseudorabies virus, bovine herpesvirus, human cytomegalovirus, respiratory syncytial virus, adeno-
associated virus type 2, foot-and -mouth disease virus, vaccina virus, sindbis virus and dengue virus 
use HS as a receptor. 
Some other sulfated polyanionic sugars were also tested for inhibition of virus binding and/or entry. 
Dextrane sulfate is a long-chain polymer of glucose containing 17-20 % sulfur. It has been used as an 
anticoagulant and also has been shown to inhibit the binding of HIV-1 to CD4+ T-lymphocytes. 
Fucoidan is sulfated fucose and has been used as anti-ulcer agent, anticoagulant and antineoplastic 
agent. 
In addition to the anionic polymers already tested, we included a novel type of polymer drug that is 
currently under development, we will call it polymer X because its chemical composition is still a 
secret.    
 
C.3.2 Test of heparin, HS, DS, fucoidan and polymer X for anti-viral activity against 
arenaviruses 
 
The pseudotypes were pre-incubated with increasing concentrations of the polymer-compounds on ice 
for 45 minutes and then added to monolayers of HeLa cells in 96 well-plates. After one hour 
incubation at 37°C, 5 % CO2 the inoculum was removed, cells washed and incubated for 48 h. 
Infection was quantified using the Steady-Glo® high sensitivity luciferase reporter gene assay 
(Promega) in a Berthold® 96 well-plate luminometer. As shown in Fig. C10, polymer X showed a 
powerful inhibition of infection by all pseudotypes of LCMV(ARM), LCMV(Cl-13) and, LFV. The 
polyanionic sugars dextrane sulfate and fucoidan showed some anti-viral activity. The soluble GAGs 
HS and heparin showed no blocking of pseudotype-infection. This is inconsistent with previous 
findings (Andrei and de Clercq, 1990) that claim that sulfated polysaccharides are potent and selective 
inhibitors of enveloped DNA and RNA viruses, were the mechanism of action of is due to the 
inhibition of virus binding to the host cell. 
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Figure C10A: Blocking of infection of cells with retroviral pseudotypes of LCMV and LFV with 
polyanionic substances. Pseudotypes (MOI = 1) were pre-incubated with the indicated concentrations of 
polymer X, heparin, heparan sulfate, dextrane sulfate, and fucoidan for one hour on ice. Pseudotypes were then 
added to monolayers of Vero cells in 96 well-plates. After 48 h, infection was quantified using the Steady-Glo® 
luciferase reporter gene assay as in Fig. C2. Luminescence is expressed as fold-increase over uninfected controls 
(n = 3 + SD). Note that the y-axis is a log scale.  
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Figure C10B: Blocking of infection of cells with retroviral pseudotypes of Guanarito, Machupo, and 
Junin with polyanionic substances. Pseudotypes (MOI = 1) were pre-incubated with the indicated 
concentrations of polymer X, dextran sulfate, heparin, and fucoidan for one hour on ice. Pseudotypes were then 
added to monolayers of Vero cells in 96 well-plates. After 48 h, infection was quantified as in Fig. C10A.  
 
C.3.3 What is the role of HS and glycosaminoglycans in arenavirus infection? 
 
To address the role of heparan sulfate in the infection of cells with arenaviruses, we made use of the 
mutant CHO cell line pgsA-745 that is deficient in UDP-D-xylose: serine-1, 3-D xylosyltransferase 
and lacks all glycosaminoglycans (Esko et al., 1985).  PsgA-754 and wild-type CHOK1 cells were 
infected with pseudotypes of LCMV (ARM53b, cl-13), LFV, Guanarito, Junin, and Machupo, as well 
as VSV-pseudotypes that do not depend on glycosaminoglycans for infection. As shown in Fig. C11, 
pgsA-745 that lack all glycosaminoglycans are more efficiently infected than normal CHOK1 cells, 
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indicating that glycosaminoglycans slightly inhibit infection. In contrast, absence of 
glycosaminoglycans resulted in a mild reduction in infection with LCMV pseudotypes, while the South 
American HF virus pseudotypes infected both cell types, pgsA-745 and CHOK1 with similar 
efficiency. Together, these data indicate only minor differences in infection of cells by arenaviruses in 
presence or absence of glycosaminoglycans, excluding an essential role as a receptor or co-receptor. 
 
 
Figure C11: Infection of arenaviruses is not dependent on glycosaminoglycans. (A) Infection of 
glycosaminoglycan-deficient and wild type CHO cells with pseudotypes: Glycosaminoglycan-deficient CHO 
mutant psgA-745 cells and CHOK1 cells were infected with the indicated pseudotypes, at an MOI of 1. 
Infection was quantified after 48 hours by luciferase assay (n = 3; + SD). (B) Blocking of pseudotype infection 
with heparan sulfate and heparin: Pseudotypes were pre-incubated with the indicated concentrations of heparan 
sulfate and heparin for one hour on ice and then added to monolayers of Vero cells (MOI of 1). Infection was 
quantified after 48 hours by luciferase assay as in A (n = 3; + SD).
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C.3.4 Evaluation of polymer X as a drug against LCMV 
 
The prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) is a powerful experimental 
model that provided novel concepts in immunology and virology that have been extended to other 
viruses, bacteria, and parasites. Investigations using the LCMV model have also uncovered the ability 
of non-cytolytic persistent viruses to avoid elimination by the host immune responses, and to induce 
disease by interfering with specialized functions of infected cells, revealing a new way by which 
viruses do harm in the absence of the classic hallmarks of cytolysis and inflammation. Moreover, there 
is increasing evidence that LCMV might be a neglected human pathogen with significant clinical 
implication. These findings together make LCMV persistent infection of the mouse a very attractive 
model system to develop and evaluate therapies to treat acute and chronic viral infections and 
associated disorders. Since no firm data on anti-viral effects of polymer X on LCMV are available at 
present, we evaluated the anti-viral potential of polymer X on live LCMV virus. First, we studied the 
ability of polymer X to block infection of VeroE6 cells with the prototypic LCMV isolate LCMV 
ARM53b. For studying the anti-viral activity of Polymer X against LCMV in a quantiative manner, we 
used FACS to determine viral infection. The virus was pre-incubated with increasing concentrations of 
the polymer-compounds on ice for 45 minutes and then added to monolayers of Vero cells in 6 well-
plates. After one hour incubation at 37°C, 5 % CO2 the inoculum was removed, cells washed twice, 
complete medium were added and plates were incubated for 20 h. After incubation, the cells were 
washed twice, detached from the plate by trypsin treatment, and re-suspended in 1% FBS/PBS. Cells 
were washed and fixated in 4% (w/v) PFA/PBS for 10 min at room temperature.  Cells were washed 
twice, re-suspended with primary antibody and incubated for 45 min on ice in the dark. After two 
additional wash steps, cells were re-suspended with secondary antibody and incubated for 45 min in 
the dark. The cell-suspention was washed and re-suspended in PBS and kept in the dark before 
measured on the flow cytometer. 
In several independent experiments we observed a significant reduction of LCMV infection with an 
IC50 of 26 (+ 7) nM (Fig. C12A). A similar reduction of infection was observed with the prototypic 
immunosuppressive LCMV isolate LCMV cl-13. In a control experiment, the activity of polymer X 
against vesicular stomatitis virus (VSV) was tested using a recombinant VSV expressing a green 
fluorescent protein marker (VSV-GFP). VSV-GFP was pre-incubated with polymer X and 
subsequently added to VeroE6 monolayers. Infection was quantified by detection of GFP in FACS. In 
contrast to the marked reduction of LCMV infection after pre-incubation with polymer X, no 
significant decrease in VSV-GFP infection was observed (Fig. C12B). Cell viability was verified by 
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staining with 7-amino-actinomycin (7-AAD) and no significant cytotoxicity was observed upon 
exposure of cells to up to 20 µM polymer X. Together, these data demonstrate a potent and significant 
anti-viral activity of polymer X against LCMV but not VSV-GFP.   
 
Figure C12: Blocking of virus infection with polyer X. Blocking of infection with LCMV ARM53b (A) and 
VSV-GFP (B): Virus was pre-incubated with the indicated concentrations of polymer X for one hour on ice and 
then added to monolayers of VeroE6 cells (MOI = 3). After 24 hours, cells were briefly trypsinized, detached 
and single cell suspensions prepared.  LCMV infection was detected by intracellular staining for LCMVNP. 
Cells were fixed, permeabilized, and stained with mAb 113 anti-LCMVNP and a FITC-labeled secondary 
antibody. Infection with VSV-GFP was detected by direct fluorescence excitation of GFP. For flow cytometry, a 
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FACSCalibur® flow cytometer was used. In histograms, the y-axis represents cell numbers and the x-axis 
fluorescence intensity (FL1-H for FITC/GFP). The dotted line represents uninfected controls and the solid line 
infected samples. Percentages of NP or GFP positive cells are given. One representative experiment out of three 
is shown. 
 
To determine the step in LCMV infection blocked by polymer X, the drug was added at different time 
points relative to infection. LCMV ARM53b was used at MOI of 0.01, 0.1, and 1. Polymer X (2 µM) 
was added exactly at the time of infection, 6 hours post infection, or 24 hours post infection. Infection 
levels were assessed after a total infection period of 48 hours by determination of LCMVNP 
expression using immunofluorescence staining with mAb 113 anti-LCMVNP (Fig. C13A) or FACS 
(Fig. C13B). Vero cells were cultivated in 8 well LabTek chamber slides and infected with 
LCMV(ARM53b) at MOI of 0.1. For one sample, LCMV were pre-incubated with the polymer X one 
hour on ice before added to the cells. For the other samples, polymer X was added at different 
timepoints after infection. After a total infection time of 48 hours, the medium/virus/polymer X 
solution removed and cells fixed at 37°C for 15 min in the dark. Cells were washed twice and 
incubated with PBS/1%(v/v) FCS for 15min at room temperature. The cells were so incubated 15 min 
with PBS/1%(v/v) FCS/0.1% (w/v) saponin. Primary antibody mAb 113 anti-LCMVNP was added and 
cells incubated for 1 hour at room temperature in the dark. Cells were washed twice and incubated with 
a FITC-conjugated secondary antibody for 45 min at room temperature in the dark. The cells were so 
washed three times before 1 drop of Vectashield were added to each fixing square and the cells 
covered with a coverglass. Images were acquired using a fluorescence microscope.  
As shown in Fig. C13, the data strongly suggest that the polymer drug blocks an early step in viral 
infection. When added at the time of infection, polymer X efficiently blocked infection of LCMV at all 
MOI tested, indicating fast inhibition of an early step in infection. Addition of polymer X after 6 or 24 
hours resulted in marked decrease in the number of infected cells, indicating efficient blocking of cell-
to-cell spread. However, the similar levels of LCMVNP expression (mean immunofluorescence 
intensities) in infected cells in presence and absence of polymer X indicate that the drug has little 
effect on LCMVNP expression once infection has occurred (Fig. C13B).  
Together, the data show that polymer X has a specific anti-viral activity against prototypic isolates of 
LCMV. The drug efficiently blocks initial steps of virus infection and prevent cell-to-cell spreading of 
virus. That means that polymer X is active in an early step of the virus lifecycle. The efficient 
neutralization of the retroviral pseudotypes of LCMV indicates further that the viral GP is the main 
drug target.  
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Figure C13: Polymer X blocks infection and cell-to-cell spread of LCMV: (A) Detection of virus infection 
and propagation by immunofluorescence. Monolayers of VeroE6 cells were infected with LCMV ARM53b at 
MOI of 0.1 and polymer X added at the indicated time points. After 48 hours, cells were fixed, permeabilized 
and stained with mAb 113 anti-LCMVNP using a FITC-conjugated secondary antibody and phalloidin-
rhodamine for counterstaining of F-actin filaments. (B) Monolayers of VeroE6 cells were infected with LCMV 
ARM53b at MOI of 0.01, 0.1, and 1 and polymer X added at the indicated time points. After 48 hours, infection 
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was determined by FACS staining for LCMVNP as in Fig. C12. The dotted line represents uninfected controls 
and the solid line infected samples. Percentages of NP positive cells are given.  
 
C.4 Production of recombinant Lassa fever virus glycoprotein 
 
The glycoprotein (GP) of Lassa fever virus (LFV) serves as virus attachment protein to its receptor on 
host cells. The GP precursor (GP-C) is post-translationally cleaved into GP1, which is implicated in 
receptor binding and GP2 that is structurally similar to the fusion active membrane proximal portions 
of the GPs of other enveloped viruses. In my studies I have identified a number of small molecule 
compounds and polymer drugs that block infection of human cells by retroviral pseudotypes 
containing the GP of LFV (LFVGP). Among the candidate drugs, compounds and substances that 
target the viral GP are of greatest interest since they are able to target the free virus and will most 
likely not interfere with crucial cell function, which will minimize their potential for adverse side 
effects.  
As pointed out in the introduction (section A.1.3), the viral GP at the surface of free LFV virions is in 
its metastable pre-fusion state. These pre-fusion state GP trimers are the functional units of target cell 
recognition, entry and fusion in arenaviruses. The production of a stable, trimeric form of LFVGP in 
its pre-fusion state is therefore of paramount importance regarding the identification of anti-viral drugs 
targeting the GP.  
To prevent the transition from the (metastable) pre-fusion into the energetically more stable post-
fusion complex, the GP2 subunits containing the fusion machinery have to be locked into a stable 
trimer that does not allow significant conformational changes. Recent attempts to express recombinant 
influenza hemagglutinin (HA) derived from the influenza strain of the 1918 pandemic faced the 
problem that the HA did not form trimers (Stevens et al., 2004). Among the potential trimerization 
domains tested by Stevens and colleagues, the recently identified foldon domain derived from 
bacteriophage T4 fibritin (Tao et al., 1997) turned out to be very efficient in the induction of trimer 
formation. The foldon domain (Fig. C14), spans the C-terminal residues G457 to L483 of the 
bacteriophage T4 fibritin and forms a trimeric complex of very high stability. Based on its properties 
as a powerful driving force for trimerization, we will construct fusion proteins of the ectrodomain of 
LFVGP and the foldon-domain (Fig. C15). These LFVGP-foldon constructs will be tested for trimer 
formation and receptor binding. Trimers formed by the LFVGP-foldon fusion proteins may be 
powerful tools for drug screening and for the investigation of the virus-cell interaction. 
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Figure C14: Structure of the foldon domain of bacteriophage T4 fibritin (from Tao et al., 1997). (a) Stereo 
diagram of the C-terminal foldon domain of a fibritin E subunit. The sidechains shown are those located in the 
hydrophobic interior formed at the interface between the subunits. (b) Ribbon diagram of the foldon domain 
looking along the trimer axis. (c) Hydrogen of the main chain formed within the foldon domain. 
 
 
Figure C15: Design of a soluble trimeric form of LFVGP locked in its pre-fusion state. For details see text. 
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C.4.1 Design of the LFVGP-foldon fusion protein 
 
Layout of the foldon cassette: 
The T4 fibritin foldon domain (GYIPEAPRDGQAYVRKDGEWVLLSTFL) 
 corresponds to residues G457 to L483 of the bacteriophage T4 fibritin (Tao et al., 1997). 
The fusion of the hole sequence of LFVGP from M(1) to LGLV(431) derived from LFV Josiah with 
the foldon domain will include a GGGS linker between the LFVGP and the foldon domain. In 
addition, we will add a flag-tag (DYKDDDDK), a throbin cleavage site (LVPR/GS), and a six His tag 
that allows purification of the soluble recombinant protein by Ni-NTA affinity chromatography.  
 
Design of the LFVGP-foldon fusion protein: 
 
M(1)…LGLV(431)GGGSGYIPEAPRDGQAYVRKDGEWVLLSTFLDYKDDDDK LVPR/GS 
HHHHHHStop 
 
          L      G     L       V(431) 
5’- TTG GGT CTA GTT GGC GGT GGA TCC GGC TAC ATC CCC GAG GCC CCG CGC GAC 
GGC CAG GCC TAC GTG CGC AAG GAC GGC GAG TGG GTG CTG CTG TCC ACC TTC CTG 
GAC TAC AAA GAC GAT GAC GAT AAA CTT GTC CCA CGT GGT TCT CAT CAC CAT CAC 
CAT CAC TAG  
Flag:  5’- GAC TAC AAA GAC GAT GAC GAT AAA-3’  
          D     Y        K     D      D       D      D      K  
 
Thrombin cleavage side: CTT GTC CCA CGT GGT TCT  
                  L      V      P      R  /   G      S 
 
A cDNA sequence containing the foldon cassette, followed by the flag-tag, thrombin cleavage site, and 
His-tag has previously been made, subcloned into a basis vector (pBluescript), and verified by double 
strand DNA sequencing. For the construction of the fusion proteins with LFVGP, the corresponding 
sequence of LFVGP M(1)… LGLV(431) derived from LFV Josiah were amplified by PCR using the 
cDNA of full-length LFVGP as a template as described in M&M.  
The fragment from LFVGP pcAGGs cDNA was amplified in PCR with the forward primer at position 
1130 and the backward primer LFEb that makes a blunt, phosphorylated 5’ end at position 1348. This 
fragment contains a restriction-site, KpnI, at position 1164 that was used for cutting the fragment. The 
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Fol 1 pBS was cut with enzymes at restriction-sites for NaeI and XhoI. The pBS was cut open with 
restrictionenzyme KpnI and XhoI. The PCR fragment and the Fol 1 pBS were ligated into the open 
pBS, that gives LFVGP-Fol 1 pBS. Then the missing fragment from LFVGP pcAGGs was cut out with 
enzymes NotI and KpnI (position 1164). The assembled fragment from LFVGP-Fol 1 pBS was cut out 
with enzymes KpnI (position 1164) and ApaI (position 1209). These two fragments were ligated into 
pcDNA3.1 (pino) that is cut opend with enzyme NotI and ApaI. This made LFVGP-Fol 1 pcDNA 
(pino) that were expressed in HEK293 cells. 
 
C.4.2 Expression and characterization of the GP1-foldon fusion proteins  
 
The LFVGP-foldon fusion proteins were expressed in HEK293 cells under serum-free conditions and 
the LFVGP-foldon fusion proteins isolated by pull-down from conditioned cell culture supernatant by 
NiNTA affinity chromatography. Protein solution was centrifuged and the supernatant removed. Pellet 
were eluted in 1 x SDS-PAGE loading reducing buffer and separated on a 12% Tri-Gly gel. Expression 
was tested by Western-blot analysis (Fig. C16). From the blot we can see that the LFGP-foldon fusion 
is efficiently secreted and that the major part of our construct gets cleaved  
 
Figure C16: Detection of recombinant LFVGP in Western-blot. LFVGP-foldon isolated from cell culture 
supernatants by NiNTA pull-down (1) and total cell lysate of HEK293T cells transfected with the full-length 
wild-type LFVGP containing a C-terminal flag-tag (2) were separated by SDS-PAGE, blotted to nitrocellulose 
and probed with mAb M2 to flag tag. Molecular masses (kDa) and the positions of the GP precursor (GPC and 
mature GP2 are indicated).  
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D. DISCUSSION 
 
The goal with this study is to find a drug that can fight Lassa fever that affects an estimated 180 
million individuals in Western Africa. There is neither an efficient cure nor an efficacious vaccine for 
LFV. With over 200 000 infections per year and several thousand deaths, LFV represents a severe 
threat for human health and a major humanitarian problem. Ribavirin is so far the only drug for 
patients infected with LFV. Ribavirin does not neutralize free virus, but works in the late steps of the 
virus lifecycle. The goal is to develop drugs that can act as “gatekeepers”, i.e. drugs that are able to 
block the early step of the virus lifecycle, the virus-receptor binding and/or entry. To block the virus 
binding and/or entry and then cell to cell spread, will give the infected patients immune system a better 
chance in generating an efficient anti-viral immune response. 
We tested small molecule derived from combinatorial chemical libraries to see if there was any 
blocking of the virus-receptor interaction. We also tested sulfated polysaccharides like dextrane 
sulfate, fucoidan, heparan sulfate and heparin that have showed anti-viral activity in studies already 
done. In addition, we tested polymer X that is an anionic polymer that has showed activity against 
HIV.  
 
D.1 Discovery of novel small molecule inhibitors of Lassa fever virus (LFV) infection from 
combinatorial chemical libraries and natural product libraries 
 
To identify potential anti-viral compounds, small molecule inhibitors of protein interaction derived 
from combinatorial chemical libraries were screened. This strategy has been used to identify several 
physiologically active inhibitors of novel biochemically not yet characterized interactions. The 
compounds/compounds mixtures were screened for their ability to block retroviral pseudotype 
infection in target cells. Retroviral pseudotypes contain LFVGP in their envelope and a luciferace 
reporter gene in their genome. The luciferase reporter gene makes the pseudotypeinfection easy to 
detect. Since live LFV is a BSL4 pathogen, studies with virus are restricted to BSL4 laboratories. The 
pseudotypes allow us to do our work under BSL2 conditions. 
Many studies on receptor-ligand binding indicate that in most cases, small clusters of amino acid 
recidues mediate the energetically most important interaction. Using Dr. Boger's libraries, 
erythropoieitin (EPO) mimetics (promote EPO receptor dimerization) (Goldberg et al., 2002), 
inhibitors of Myc/Max dimerization (Berg et al., 2002), inhibitors of androgen receptor binding to 
DNA (Boger et al., 2000a), inhibitors of LEF-1/β-catenin dimerization (Boger et al., 2000b), and 
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inhibitors of the binding of the protease MMP-2 to αvß3 integrin have been discovered (Silletti et al., 
2001; Boger et al., 2001). That makes us think that small molecules, interacting with the reseptor-
binding site for the virus, can block virus infection in cells.   
We screened combinatorial libraries of small molecules that consist of imidodiacetic acid-based, 
pyrrolidine-based peptidomimetic but also heterolytic compounds. The compounds were not attached 
to solid supports making them immediately available for binding or functional assays. I tested 13 
complete libraries. Each library had 80 wells that contained single compounds or mixtures of 4-10 
compounds (that made the screening more effective). Totally this gave a number > 10,000 compounds. 
Duplicate screening resulted in the identification of circa 4-5% compounds/mixtures that showed 
reproducible reduced LFV-PS infection by > 50%. To test our candidate for specificity, we screened 
the compounds for inhibition of VSV-pseudotype infection. VSVGP is structurally unrelated to 
LFVGP and binds to a different receptor. If the compounds are specific, they should not affect the 
infection of target cells by VSV-pseudotype. My screening together with previous screenings done in 
the lab of another 31 libraries, corresponding to > 50, 000 compounds yielded 157 (4.5%) 
compounds/mixtures that showed reproducible reduced LFV-PS infection.  Determination of target 
specificity revealed that 32 single compounds and 53 compound mixtures out of a total of 125 
specifically reduced infection in LFV-PS but not VSV-PS. We found difference in specificity between 
different libraries; some were very consistent, with most candidate compounds being specific for 
inhibition of LFV-GP infection, when other compounds showed effect both against LFV-PS and VSV-
GP. 
A selection of 17 individual compounds was then further characterized. The selection was made based 
on the extent of inhibition, degree of specificity, and also chemical considerations, raised by our 
chemist collaborators. The selected compounds were tested for inhibition of pseudotype infection in 
different cell-lines (He-La, A549 and VeroE6) that showed that the candidate compounds had 
consistent blocking of LFV-PS infection in all cell lines and were independent of the specific target.  
The determination of the dose-response of the individual compounds was also tested on the different 
cell lines. We found 8 candidate compounds to be particularly good selective inhibitors against LFV-
PS. Many of these candidate compounds were also active against the human pathogenic South 
American HF viruses Guanarito, Junin and Machupo. The responses to the compounds in the different 
NWAV-PS were very similar as in LFV-PS. Structurally our candidate compounds were hydrophobic 
molecules with a high degree of aromaticity. Comparison of the most active structures revealed that an 
overall tripartite symmetry was a common structural theme. Examples are shown in Fig. D1. 
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Figure D1: Representative examples of candidate compounds 
 
Our candidate drugs may block one or several of the following steps: virus-receptor binding, binding 
of the viral GP to a yet unknown co-receptor, virus internalization by vesicles, and pH-dependent 
fusion of the late endosome membrane with the viral membrane that releases the virus into the 
cytoplasm (Fig. D2). More or less modified, these compounds are small and an oral administration of 
the drug is therefore possible (as far as the stability and absorption in the GI-tract not cause any 
problems). An oral route of administration would be of importance for better viability for the patients 
when this does not need any specialized assistance.   
 
D.2 Evaluation of polyanionic compounds as anti-arenaviral drugs 
 
We tested polyanionic compounds as anti-arenaviral drugs because they have from earlier studies 
showed antiviral activity against arenaviruses. They were found to be selective inhibitors, whereas the 
compounds were not inhibitory to cell growth. In Graciela Andrei and Erik De Clercqs paper (1990) it 
is claimed that the polyanionic compounds worked at the early step of infection of arenaviruses, by 
inhibiting reseptor binding and/or fusion and entry. In general poly-anionic compounds have showed 
activity against HIV-1 and other viruses. The anti-HIV-1 activity decreased with increasing the 
hydrophobicity (Clercq et al, 1995). In our study, we tested heparin, heparin sulfate (HS), dextrane 
sulfate and fucoidan. We selected those because many viruses utilize glycosaminoglycans, 
predominantly HS as receptor or co-receptors, together with other molecules. If a virus use HS as a 
receptor or co-receptor, their surface glycoproteins must contain binding sites for HS. By adding the 
glycosaminoglycans to the viruses, the binding site for glycosaminoglycans will be occupied and the 
virus will not be able to infect the target cell. Our results showed that dextrane sulfate and fucoidan 
had some anti-viral activity. Heparin and HS did not show any significant anti-viral activity. The 
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results did not come out as we expected them from the study already done (Andrei and de Clercq, 
1990). The glycosaminoglycans did not show any significant anti-viral activity on the receptor 
binding/fusion/entry stage. The glycosaminoglycans must therefore have a different mechanism of 
action than Clercq et al claimed. The glycosaminoglycans antiviral-effect may have a mechanism 
related to a later step in the virus life-cycle than the steps we tested (virus receptor 
binding/fusion/entry). 
We can suggest a general model for the (normally weak) anti-viral effect of polyanionic compounds 
and the increased infection often seen after application of polycations. Increased infection after 
application of polycations is caused of the decrease in repulsions between the viruses. Polycations are 
of the opposite charge than the surface of the virus particles that are negatively charged (because of the 
sugars attached). Polycations will therefore lower the surface energy of the viruses so they can easier 
go together in clusters. A cluster of viruses will then be able to enter the cell through one receptor 
instead of one single virus. We will then see an increased infection. 
If we look at the different activities of heparin/HS vs. dextrane sulfate/fucoidan, and polymer X, it 
seems like it is not only the charge of the polymer that is responsible for anti-viral activity. The 
hydrophobicity of the compound is also of importance. The more hydrophobic the compound is, the 
better anti-viral activity. Polymer X shows broad anti-viral activity. It shows nearly full inhibition of 
infection of all the pseudotypes. Polymer X has the same charge as the polyanionic compounds, but is 
more hydrophobic. Tested on real virus (LCMV and VSV), the polymer X shows specificity. Polymer 
X acts at the step of infection. If it blocks the receptor-binding, fusion and/or entry is still unknown. 
Since the polymer X act at the step of infection, it can inhibit cell-to-cell spread. The polymer X should 
for that reason be used early in a virus-infection. Anyway, if cells are protected against re-infection in 
an infected individual, the immune system will have a greater opportunity to clear the infection. 
Polymer X is a huge molecule; it is too big to be absorbed in the GI-tract and must be administrated 
i.v. When the mechanism of action is understood for polymer X and the small molecule drugs, it is a 
possibility to combine the two drugs to make a better anti-viral effect. 
 
D.3 Production of recombinant Lassa fever virus glycoprotein 
 
Among the candidate drugs, the compounds and substrates that target the viral GP are of greatest 
interest since they are able to target the free virus and will most likely not interfere with crucial cell 
function, which will minimize their potential for adverse side effects. The viral GP at the surface of 
free LFV virions is in its metastable pre-fusion state. These pre-fusion state GP trimers are the 
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functional units of target cell recognition, entry and fusion in arenaviruses. The production of a stable, 
trimeric form of LFVGP in its prefusion state is therefore important regarding the identification of 
anti-viral drugs targeting the GP. It is critical to have the GP in its prefusion state, because this is the 
state where the drugs have to be active (before infection of the cell). The conformation of the GP is 
changed in its post-fusion state and the drugs may not recognize this conformation and the study will 
then not be correct. To prevent the transition from the (metastable) pre-fusion into the energetically 
more stable post-fusion complex, the GP2 subunits contain the fusion machinery have to be locked into 
a stable trimer that does not allow significant conformational changes. These LFVGP-foldon 
constructs will be tested for trimer formation and receptor-binding. Someone else has already done a 
similar approach (Eschli et al., 2006) and that worked out well.  Our approach worked out as expected. 
We got expression of LFVGP-foldon and 80% of the constructs were cleaved. Preventing this cleavage 
by mutate its cleavage site, can possible give the construct more stability. 
 
D.4 Outlook 
 
My work at Scripps resulted in the identification and first characterization of a number of candidate 
small molecules that show specific anti-viral activity against pseudotypes of LFV and other human 
pathogenic arenaviruses and in the demonstration of a potent anti-viral effect of a novel polymer drug 
against LCMV. My results provide the basis for the following studies that will further characterize and 
optimize our drug candidates.   
 
D.4.1 Further validation of candidate compounds  
 
Determination of the drug target: To avoid undesired side effects of our small molecule drugs, we 
will select for compounds that efficiently block LFV infection by specifically targeting the viral GP 
but not cellular receptor molecules. For this purpose, the recombinant soluble form of LFVGP, which I 
made (Results, section C4) will be used. 
Validation of activity of candidate drugs against live LFV: Activity of candidate drugs against live 
LFV will be tested in a BSL4 facility by Dr. Christina Spiropoulou from the Special Pathogens Branch 
of the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. The Special Pathogens 
Branch has also a well-established small animal model (guinea pig) for LFV infection for later in vivo 
testing of candidate compounds.  
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D.4.2 Determination of the mechanism of action of candidate drugs  
 
Once we have identified specific compounds that block infection of human target cells with LFV in an 
efficient manner, we will start to investigate the exact mechanism of their activity. The drugs could 
target the following steps or combinations thereof: 1) the binding site(s) on LFVGP for its cellular 
receptor(s), 2) the pre-fusion conformation of LFVGP as present at the virion surface, and 3) A 
conformational intermediate of LFVGP occurring during pH-dependent membrane fusion (Fig. D2). 
  
 
Figure D2: Potential steps in LFVGP-mediated infection that may be blocked by our drugs.  
 
D.4.3 Extension of small molecule screening to other drug targets and other emerging pathogens  
 
Although inhibition of virus-host cell binding and entry is a very promising anti-viral strategy for 
highly pathogenic viruses, it is a good idea to aim at the development of high throughput screening 
assays targeting other steps in virus multiplication. One attractive target for inhibitors is the proteolytic 
processing of LFVGP. We and others have shown that the GPs of the Old World arenaviruses LFV and 
LCMV are cleaved by the subtilase SKI-1/S1P and that processing of the GP is essential for viral 
infectivity (Lenz et al., 2001; Beyer et al., 2003; Kunz et al., 2003). Since S1P protease is involved in 
cholesterol metabolism of the host cell, a temporary block of S1P activity could be compensated by 
dietary cholesterol supplementation. The S1P protease appears therefore as an attractive drug target to 
interfere with the processing of LFVGP and thus virus multiplication. Another promising target for 
interference with viral multiplication is the assembly of LFV virions. Since the presence of the viral 
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GP is absolutely required for LFV particles to be infectious, GP incorporation during virus assembly at 
the plasma membrane is another promising target for interference by anti-viral drugs. Based on the 
incorporation of recombinant LFVGP in our pseudovirion system, one might try to establish an assay 
system for the screening for small molecule drugs that prevent the formation of mature LFVGP whose 
then can be incorporated into infections particles.   
 
The identification of candidate small molecule anti-viral drugs against emerging viruses will 
likely be of enormous benefit for the development of novel anti-viral therapeutics for these severe 
human pathogens. Furthermore, the elucidation of their mechanism of action will shed light on 
the molecular mechanism underlying virus-receptor binding, entry, and virus GP-mediated 
membrane fusion of human pathogenic arenaviruses and thus identify novel drug targets and 
contribute to subsequent rational drug design. 
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